<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644620303792</prism:url><dc:identifier>doi:10.1016/j.drudis.2020.09.022</dc:identifier><eid>1-s2.0-S1359644620303792</eid><prism:doi>10.1016/j.drudis.2020.09.022</prism:doi><pii>S1359-6446(20)30379-2</pii><dc:title>Therapeutic aspects of the Axl/Gas6 molecular system </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><prism:volume>25</prism:volume><prism:issueIdentifier>12</prism:issueidentifier><prism:startingPage>2130</prism:startingpage><prism:endingPage>2148</prism:endingpage><prism:pageRange>2130-2148</prism:pagerange><prism:number>12</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2020-12-31</prism:coverdate><prism:coverDisplayDate>December 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Di Stasi, Rossella</dc:creator><dc:creator>De Rosa, Lucia</dc:creator><dc:creator>D’Andrea, Luca D.</dc:creator><dc:description>
                  Axl receptor tyrosine kinase (RTK) and its ligand, growth arrest-specific protein 6 (Gas6), are involved in several biological functions and participate in the development and progression of a range of malignancies and autoimmune disorders. In this review, we present this molecular system from a drug discovery perspective, highlighting its therapeutic implications and challenges that need to be addressed. We provide an update on Axl/Gas6 axis biology, exploring its role in fields ranging from angiogenesis, cancer development and metastasis, immune response and inflammation to viral infection. Finally, we summarize the molecules that have been developed to date to target the Axl/Gas6 molecular system for therapeutic and diagnostic applications.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644620303792" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644620303792" rel="scidir"/></link></coredata><objects><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="89" height="78" size="3303">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="65" height="101" size="3154">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="84" height="102" size="4251">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="518" size="87624">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="598" size="68419">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="685" size="101523">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="745" size="109631">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="681" size="85838">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="515" size="95525">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="885" height="518" size="61185">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="188" height="164" size="24424">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="105" height="163" size="14722">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="134" height="163" size="17773">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="136" size="9365">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="157" size="7009">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="200" height="164" size="9196">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="184" height="164" size="8847">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="201" height="164" size="7924">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="135" size="6784">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="128" size="6666">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="394" height="344" size="37416">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="292" height="453" size="33522">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="372" height="453" size="47164">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2293" size="841662">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2648" size="616212">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="3036" size="826322">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="3302" size="933771">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="3017" size="856318">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2280" size="799704">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3917" height="2292" size="504369">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620303792-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85092141146</scopus-id><scopus-eid>2-s2.0-85092141146</scopus-eid><pubmed-id>33002607</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85092141146" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200928">2020-09-28</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200928">2020-09-28</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20201130">2020-11-30</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20201130">2020-11-30</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-11-30T16:52:54</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644620303792</xocs:eid>
      <xocs:pii-formatted>S1359-6446(20)30379-2</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644620303792</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2020.09.022</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644620X00134</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20201130">2020-11-30T17:46:00.166276Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20201201</xocs:date-search-begin>
      <xocs:date-search-end>20201231</xocs:date-search-end>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1601313513">2020-09-28T17:18:33.87503Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authlast grantsponsor highlightsabst orcid primabst pubtype ref teaserabst vitae</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>25</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>25</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>12</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>12</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 25, Issue 12</xocs:vol-iss-suppl-text>
      <xocs:sort-order>10</xocs:sort-order>
      <xocs:first-fp>2130</xocs:first-fp>
      <xocs:last-lp>2148</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>2130</xocs:first-page>
         <xocs:last-page>2148</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202012</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>December 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-12-01</xocs:cover-date-start>
      <xocs:cover-date-end>2020-12-31</xocs:cover-date-end>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>REVIEWS</xocs:hub-sec-title>
         <xocs:hub-sec>
            <xocs:hub-sec-title>Keynote</xocs:hub-sec-title>
         </xocs:hub-sec>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>THERAPEUTICASPECTSAXLGAS6MOLECULARSYSTEM</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>DISTASI</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>R</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Axl/Gas6 axis: architecture and biology of the system</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Axl/Gas6 proteins in angiogenesis, cancer development, and metastasis</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Axl/Gas6 proteins in the regulation of immune response: roles in multiple sclerosis and other autoimmune diseases</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Role of Axl/Gas6 proteins in viral infection</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Axl/Gas6 targeting in biomedicine</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Axl/Gas6 small-molecule inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Tyrosine kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Nontyrosine kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Aptamers</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Protein-based molecules</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Axl-targeting antibodies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Gas6-neutralizing proteins</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>rGas6</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Cell-based therapy</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgment</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>LEMKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>a009076</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>LEMKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>327</xocs:ref-first-fp>
            <xocs:ref-last-lp>336</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>GRAHAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>769</xocs:ref-first-fp>
            <xocs:ref-last-lp>785</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-normalized-surname>BYERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>279</xocs:ref-first-fp>
            <xocs:ref-last-lp>290</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>852</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>DUNNE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>164</xocs:ref-first-fp>
            <xocs:ref-last-lp>175</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>HSIEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>36956</xocs:ref-first-fp>
            <xocs:ref-last-lp>36970</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>425</xocs:ref-first-fp>
            <xocs:ref-last-lp>429</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>GJERDRUM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1124</xocs:ref-first-fp>
            <xocs:ref-last-lp>1129</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>WIUM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-article-number>166</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0055">
            <xocs:ref-normalized-surname>BELLAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-article-number>1807</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0060">
            <xocs:ref-normalized-surname>MEERTENS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>324</xocs:ref-first-fp>
            <xocs:ref-last-lp>333</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0065">
            <xocs:ref-normalized-surname>SHIMOJIMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>S259</xocs:ref-first-fp>
            <xocs:ref-last-lp>263</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0070">
            <xocs:ref-normalized-surname>BELLAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>5070</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0075">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>153</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0080">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1988</xocs:ref-pub-year>
            <xocs:ref-first-fp>1952</xocs:ref-first-fp>
            <xocs:ref-last-lp>1956</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0085">
            <xocs:ref-normalized-surname>OBRYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1991</xocs:ref-pub-year>
            <xocs:ref-first-fp>5016</xocs:ref-first-fp>
            <xocs:ref-last-lp>5031</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0090">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>7</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0095">
            <xocs:ref-normalized-surname>YAMAGATA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>621</xocs:ref-first-fp>
            <xocs:ref-last-lp>632</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0100">
            <xocs:ref-normalized-surname>SASAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>80</xocs:ref-first-fp>
            <xocs:ref-last-lp>87</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0105">
            <xocs:ref-normalized-surname>STITT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>661</xocs:ref-first-fp>
            <xocs:ref-last-lp>670</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0110">
            <xocs:ref-normalized-surname>SADAHIRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3002</xocs:ref-first-fp>
            <xocs:ref-last-lp>3013</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0115">
            <xocs:ref-normalized-surname>LEW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-article-number>e03385</xocs:ref-article-number>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0120">
            <xocs:ref-normalized-surname>HEALY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>L1273</xocs:ref-first-fp>
            <xocs:ref-last-lp>L1281</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0125">
            <xocs:ref-normalized-surname>PRIETO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>295</xocs:ref-first-fp>
            <xocs:ref-last-lp>314</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0130">
            <xocs:ref-normalized-surname>NAKANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>387</xocs:ref-first-fp>
            <xocs:ref-last-lp>392</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0135">
            <xocs:ref-normalized-surname>LAURANCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>196</xocs:ref-first-fp>
            <xocs:ref-last-lp>203</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0140">
            <xocs:ref-normalized-surname>LACROIX</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>S27</xocs:ref-first-fp>
            <xocs:ref-last-lp>S29</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0145">
            <xocs:ref-normalized-surname>SCHOUMACHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0150">
            <xocs:ref-normalized-surname>BRAUNGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>2619</xocs:ref-first-fp>
            <xocs:ref-last-lp>2631</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0155">
            <xocs:ref-normalized-surname>LINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>35</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0160">
            <xocs:ref-normalized-surname>TONDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2387614</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0165">
            <xocs:ref-normalized-surname>ROTHLIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1124</xocs:ref-first-fp>
            <xocs:ref-last-lp>1136</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0170">
            <xocs:ref-normalized-surname>NI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>662</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0175">
            <xocs:ref-normalized-surname>ZAGORSKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>920</xocs:ref-first-fp>
            <xocs:ref-last-lp>928</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0180">
            <xocs:ref-normalized-surname>VANDERMEER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2460</xocs:ref-first-fp>
            <xocs:ref-last-lp>2469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0185">
            <xocs:ref-normalized-surname>GRABIEC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>855</xocs:ref-first-fp>
            <xocs:ref-last-lp>860</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0190">
            <xocs:ref-normalized-surname>GRABIEC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0195">
            <xocs:ref-normalized-surname>ORME</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>58</xocs:ref-first-fp>
            <xocs:ref-last-lp>68</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0200">
            <xocs:ref-normalized-surname>MILLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>623</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0205">
            <xocs:ref-normalized-surname>EKMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>838</xocs:ref-first-fp>
            <xocs:ref-last-lp>844</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0210">
            <xocs:ref-normalized-surname>STAUFER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>e3135</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0215">
            <xocs:ref-normalized-surname>WEINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>283</xocs:ref-first-fp>
            <xocs:ref-last-lp>293</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0220">
            <xocs:ref-normalized-surname>RANKIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-article-number>103</xocs:ref-article-number>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0225">
            <xocs:ref-normalized-surname>TAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4044</xocs:ref-first-fp>
            <xocs:ref-last-lp>4055</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0230">
            <xocs:ref-normalized-surname>LINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1073</xocs:ref-first-fp>
            <xocs:ref-last-lp>1090</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0235">
            <xocs:ref-normalized-surname>HOLLAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>9294</xocs:ref-first-fp>
            <xocs:ref-last-lp>9303</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0240">
            <xocs:ref-normalized-surname>GALLICCHIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1970</xocs:ref-first-fp>
            <xocs:ref-last-lp>1976</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0245">
            <xocs:ref-normalized-surname>MCSHANE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1286</xocs:ref-first-fp>
            <xocs:ref-last-lp>1295</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0250">
            <xocs:ref-normalized-surname>NALWOGA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>e0146823</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0255">
            <xocs:ref-normalized-surname>CORNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1496</xocs:ref-first-fp>
            <xocs:ref-last-lp>1512</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0260">
            <xocs:ref-normalized-surname>GOYETTE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1476</xocs:ref-first-fp>
            <xocs:ref-last-lp>1490</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0265">
            <xocs:ref-normalized-surname>TANIGUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>259</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0270">
            <xocs:ref-normalized-surname>BUDAGIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4260</xocs:ref-first-fp>
            <xocs:ref-last-lp>4270</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0275">
            <xocs:ref-normalized-surname>MUDDULURU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2888</xocs:ref-first-fp>
            <xocs:ref-last-lp>2899</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0280">
            <xocs:ref-normalized-surname>RAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2051</xocs:ref-first-fp>
            <xocs:ref-last-lp>2069</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0285">
            <xocs:ref-normalized-surname>NGUYEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>294</xocs:ref-first-fp>
            <xocs:ref-last-lp>297</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0290">
            <xocs:ref-normalized-surname>GHEITA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1279</xocs:ref-first-fp>
            <xocs:ref-last-lp>1286</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0295">
            <xocs:ref-normalized-surname>BASSYOUNI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>53</xocs:ref-first-fp>
            <xocs:ref-last-lp>59</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0300">
            <xocs:ref-normalized-surname>EKMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-article-number>R158</xocs:ref-article-number>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0305">
            <xocs:ref-normalized-surname>SALMI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>6156493</xocs:ref-article-number>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0310">
            <xocs:ref-normalized-surname>BELLAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>2696173</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0315">
            <xocs:ref-normalized-surname>BINDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>277</xocs:ref-first-fp>
            <xocs:ref-last-lp>287</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0320">
            <xocs:ref-normalized-surname>DENDROU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>545</xocs:ref-first-fp>
            <xocs:ref-last-lp>558</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0325">
            <xocs:ref-normalized-surname>FOURGEAUD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>240</xocs:ref-first-fp>
            <xocs:ref-last-lp>244</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0330">
            <xocs:ref-normalized-surname>SCUTERA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>3004</xocs:ref-first-fp>
            <xocs:ref-last-lp>3013</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0335">
            <xocs:ref-normalized-surname>SHANKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>5638</xocs:ref-first-fp>
            <xocs:ref-last-lp>5648</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0340">
            <xocs:ref-normalized-surname>GRUBER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>16320</xocs:ref-first-fp>
            <xocs:ref-last-lp>16335</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0345">
            <xocs:ref-normalized-surname>WEINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>49</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0350">
            <xocs:ref-normalized-surname>HOEHN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>11</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0355">
            <xocs:ref-normalized-surname>BINDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5195</xocs:ref-first-fp>
            <xocs:ref-last-lp>5206</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0360">
            <xocs:ref-normalized-surname>WOOLISCROFT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>34</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0365">
            <xocs:ref-normalized-surname>SAINAGHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-article-number>406483</xocs:ref-article-number>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0370">
            <xocs:ref-normalized-surname>SAINAGHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>138</xocs:ref-first-fp>
            <xocs:ref-last-lp>142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0375">
            <xocs:ref-normalized-surname>SAINAGHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>65</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0380">
            <xocs:ref-normalized-surname>MEERTENS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>544</xocs:ref-first-fp>
            <xocs:ref-last-lp>557</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0385">
            <xocs:ref-normalized-surname>AMARA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>461</xocs:ref-first-fp>
            <xocs:ref-last-lp>469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0390">
            <xocs:ref-normalized-surname>BHATTACHARYYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>18</xocs:ref-first-fp>
            <xocs:ref-last-lp>28</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0395">
            <xocs:ref-normalized-surname>HASTINGS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>339</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0400">
            <xocs:ref-normalized-surname>HASTINGS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>558</xocs:ref-first-fp>
            <xocs:ref-last-lp>568</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0405">
            <xocs:ref-normalized-surname>RICHARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2024</xocs:ref-first-fp>
            <xocs:ref-last-lp>2029</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0410">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>302</xocs:ref-first-fp>
            <xocs:ref-last-lp>309</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0415">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1183</xocs:ref-first-fp>
            <xocs:ref-last-lp>1189</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0420">
            <xocs:ref-normalized-surname>STRANGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0425">
            <xocs:ref-normalized-surname>DORTENZIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2195</xocs:ref-first-fp>
            <xocs:ref-last-lp>2198</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0430">
            <xocs:ref-normalized-surname>WHITE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>479</xocs:ref-first-fp>
            <xocs:ref-last-lp>489</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0435">
            <xocs:ref-normalized-surname>VERSTEEG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>508</xocs:ref-first-fp>
            <xocs:ref-last-lp>516</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0440">
            <xocs:ref-normalized-surname>FONTES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>837</xocs:ref-first-fp>
            <xocs:ref-last-lp>838</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0445">
            <xocs:ref-normalized-surname>ESPINDOLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1443</xocs:ref-first-fp>
            <xocs:ref-last-lp>1456</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0450">
            <xocs:ref-normalized-surname>BARCENA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>670</xocs:ref-first-fp>
            <xocs:ref-last-lp>678</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0455">
            <xocs:ref-normalized-surname>SMIRNE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0460">
            <xocs:ref-normalized-surname>LANDOLT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>e14091</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0465">
            <xocs:ref-normalized-surname>HOLLAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1544</xocs:ref-first-fp>
            <xocs:ref-last-lp>1554</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0470">
            <xocs:ref-normalized-surname>MYERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2104</xocs:ref-first-fp>
            <xocs:ref-last-lp>2110</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0475">
            <xocs:ref-normalized-surname>TAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>6807</xocs:ref-first-fp>
            <xocs:ref-last-lp>6825</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0480">
            <xocs:ref-normalized-surname>FLEUREN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>12753</xocs:ref-first-fp>
            <xocs:ref-last-lp>12768</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0485">
            <xocs:ref-normalized-surname>BENBATALLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2289</xocs:ref-first-fp>
            <xocs:ref-last-lp>2300</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0490">
            <xocs:ref-normalized-surname>BENBATALLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2443</xocs:ref-first-fp>
            <xocs:ref-last-lp>2452</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0495">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1138</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0500">
            <xocs:ref-normalized-surname>BRAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2601</xocs:ref-first-fp>
            <xocs:ref-last-lp>2612</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0505">
            <xocs:ref-normalized-surname>TUTUSAUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>349</xocs:ref-first-fp>
            <xocs:ref-last-lp>368</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0510">
            <xocs:ref-normalized-surname>ZHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>37</xocs:ref-first-fp>
            <xocs:ref-last-lp>44</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0515">
            <xocs:ref-normalized-surname>HIRSCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>199</xocs:ref-first-fp>
            <xocs:ref-last-lp>210</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0520">
            <xocs:ref-normalized-surname>CRUZLOPEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>21620</xocs:ref-first-fp>
            <xocs:ref-last-lp>21626</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0525">
            <xocs:ref-normalized-surname>OU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1643</xocs:ref-first-fp>
            <xocs:ref-last-lp>1652</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0530">
            <xocs:ref-normalized-surname>JIMBO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5152</xocs:ref-first-fp>
            <xocs:ref-last-lp>5167</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0535">
            <xocs:ref-normalized-surname>FUJINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1047</xocs:ref-first-fp>
            <xocs:ref-last-lp>1062</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0540">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1905</xocs:ref-first-fp>
            <xocs:ref-last-lp>1915</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0545">
            <xocs:ref-normalized-surname>HART</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>7</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0550">
            <xocs:ref-normalized-surname>CUI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>6342</xocs:ref-first-fp>
            <xocs:ref-last-lp>6363</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0555">
            <xocs:ref-normalized-surname>MORI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>556</xocs:ref-first-fp>
            <xocs:ref-last-lp>565</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0560">
            <xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1116</xocs:ref-first-fp>
            <xocs:ref-last-lp>1119</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0565">
            <xocs:ref-normalized-surname>SCHROEDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1251</xocs:ref-first-fp>
            <xocs:ref-last-lp>1254</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0570">
            <xocs:ref-normalized-surname>ONKEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>9876</xocs:ref-first-fp>
            <xocs:ref-last-lp>9889</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0575">
            <xocs:ref-normalized-surname>LAUTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0580">
            <xocs:ref-normalized-surname>YANAGITA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>42364</xocs:ref-first-fp>
            <xocs:ref-last-lp>42369</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0585">
            <xocs:ref-normalized-surname>NAKANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>387</xocs:ref-first-fp>
            <xocs:ref-last-lp>392</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0590">
            <xocs:ref-normalized-surname>HASANBASIC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2790</xocs:ref-first-fp>
            <xocs:ref-last-lp>2797</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0595">
            <xocs:ref-normalized-surname>PAOLINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>508</xocs:ref-first-fp>
            <xocs:ref-last-lp>512</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0600">
            <xocs:ref-normalized-surname>NAGAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>18229</xocs:ref-first-fp>
            <xocs:ref-last-lp>18234</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0605">
            <xocs:ref-normalized-surname>KIMANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>43908</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0610">
            <xocs:ref-normalized-surname>CERCHIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2291</xocs:ref-first-fp>
            <xocs:ref-last-lp>2303</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0615">
            <xocs:ref-normalized-surname>NUZZO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>256</xocs:ref-first-fp>
            <xocs:ref-last-lp>263</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0620">
            <xocs:ref-normalized-surname>KANLIKILICER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>251</xocs:ref-first-fp>
            <xocs:ref-last-lp>262</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0625">
            <xocs:ref-normalized-surname>CRAIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>136</xocs:ref-first-fp>
            <xocs:ref-last-lp>147</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0630">
            <xocs:ref-normalized-surname>DEROSA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>894</xocs:ref-first-fp>
            <xocs:ref-last-lp>905</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0635">
            <xocs:ref-normalized-surname>SCHUMACHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>1854</xocs:ref-first-fp>
            <xocs:ref-last-lp>1857</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0640">
            <xocs:ref-normalized-surname>YE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5254</xocs:ref-first-fp>
            <xocs:ref-last-lp>5264</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0645">
            <xocs:ref-normalized-surname>DUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>e12777</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0650">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>3442</xocs:ref-first-fp>
            <xocs:ref-last-lp>3455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0655">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>297</xocs:ref-first-fp>
            <xocs:ref-last-lp>305</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0660">
            <xocs:ref-normalized-surname>LECONET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>5405</xocs:ref-first-fp>
            <xocs:ref-last-lp>5414</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0665">
            <xocs:ref-normalized-surname>LECONET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2806</xocs:ref-first-fp>
            <xocs:ref-last-lp>2816</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0670">
            <xocs:ref-normalized-surname>BOSHUIZEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>203</xocs:ref-first-fp>
            <xocs:ref-last-lp>212</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0675">
            <xocs:ref-normalized-surname>KOOPMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>e128199</xocs:ref-article-number>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0680">
            <xocs:ref-normalized-surname>SHARP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0685">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1686525</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0690">
            <xocs:ref-normalized-surname>JIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>125</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0695">
            <xocs:ref-normalized-surname>NIMMAGADDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>635</xocs:ref-first-fp>
            <xocs:ref-last-lp>640</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0700">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>511</xocs:ref-first-fp>
            <xocs:ref-last-lp>518</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0705">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3974</xocs:ref-first-fp>
            <xocs:ref-last-lp>3979</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0710">
            <xocs:ref-normalized-surname>MOODY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1340</xocs:ref-first-fp>
            <xocs:ref-last-lp>1349</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0715">
            <xocs:ref-normalized-surname>FISHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>727</xocs:ref-first-fp>
            <xocs:ref-last-lp>735</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0720">
            <xocs:ref-normalized-surname>KARIOLIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>977</xocs:ref-first-fp>
            <xocs:ref-last-lp>983</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0725">
            <xocs:ref-normalized-surname>KARIOLIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>183</xocs:ref-first-fp>
            <xocs:ref-last-lp>198</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0730">
            <xocs:ref-normalized-surname>DUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5784</xocs:ref-first-fp>
            <xocs:ref-last-lp>5792</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0735">
            <xocs:ref-normalized-surname>TSIPERSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>e15748</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0740">
            <xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>333</xocs:ref-first-fp>
            <xocs:ref-last-lp>342</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0745">
            <xocs:ref-normalized-surname>VANDENBRAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>671</xocs:ref-first-fp>
            <xocs:ref-last-lp>680</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0750">
            <xocs:ref-normalized-surname>TONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1971</xocs:ref-first-fp>
            <xocs:ref-last-lp>1981</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0755">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>575</xocs:ref-first-fp>
            <xocs:ref-last-lp>582</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0760">
            <xocs:ref-normalized-surname>PENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>e0219788</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0765">
            <xocs:ref-normalized-surname>CHO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3846</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0770">
            <xocs:ref-normalized-surname>WEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>49</xocs:ref-first-fp>
            <xocs:ref-last-lp>58</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0775">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>4795171</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0780">
            <xocs:ref-normalized-surname>MOLLARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>907</xocs:ref-first-fp>
            <xocs:ref-last-lp>912</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0785">
            <xocs:ref-normalized-surname>LAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0790">
            <xocs:ref-normalized-surname>TAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>318</xocs:ref-first-fp>
            <xocs:ref-last-lp>327</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0795">
            <xocs:ref-normalized-surname>OSLOB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4880</xocs:ref-first-fp>
            <xocs:ref-last-lp>4884</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0800">
            <xocs:ref-normalized-surname>BURBRIDGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1749</xocs:ref-first-fp>
            <xocs:ref-last-lp>1762</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0805">
            <xocs:ref-normalized-surname>CUI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>33</xocs:ref-first-fp>
            <xocs:ref-last-lp>40</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0810">
            <xocs:ref-normalized-surname>FAVATA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0815">
            <xocs:ref-normalized-surname>MAHADEVAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>3909</xocs:ref-first-fp>
            <xocs:ref-last-lp>3919</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0820">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>7031</xocs:ref-first-fp>
            <xocs:ref-last-lp>7041</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0825">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>129</xocs:ref-first-fp>
            <xocs:ref-last-lp>134</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0830">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>83</xocs:ref-first-fp>
            <xocs:ref-last-lp>93</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0835">
            <xocs:ref-normalized-surname>LEESHERICK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6722</xocs:ref-first-fp>
            <xocs:ref-last-lp>6736</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0840">
            <xocs:ref-normalized-surname>YAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>833</xocs:ref-first-fp>
            <xocs:ref-last-lp>844</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0845">
            <xocs:ref-normalized-surname>BONFILS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0850">
            <xocs:ref-normalized-surname>PATWARDHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>4093</xocs:ref-first-fp>
            <xocs:ref-last-lp>4109</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0855">
            <xocs:ref-normalized-surname>RHO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>253</xocs:ref-first-fp>
            <xocs:ref-last-lp>262</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0860">
            <xocs:ref-normalized-surname>CHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>556</xocs:ref-first-fp>
            <xocs:ref-last-lp>568</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0865">
            <xocs:ref-normalized-surname>QIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>8009</xocs:ref-first-fp>
            <xocs:ref-last-lp>8016</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0870">
            <xocs:ref-normalized-surname>RUVOLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2048</xocs:ref-first-fp>
            <xocs:ref-last-lp>2057</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0875">
            <xocs:ref-normalized-surname>YASUHIRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>999</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0880">
            <xocs:ref-normalized-surname>YOKOYAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1996</xocs:ref-first-fp>
            <xocs:ref-last-lp>2008</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0885">
            <xocs:ref-normalized-surname>GAJIWALA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>15705</xocs:ref-first-fp>
            <xocs:ref-last-lp>15716</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0890">
            <xocs:ref-normalized-surname>SASAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>44164</xocs:ref-first-fp>
            <xocs:ref-last-lp>44170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>DISTASIX2020X2130</xocs:refkey3>
         <xocs:refkey4lp>DISTASIX2020X2130X2148</xocs:refkey4lp>
         <xocs:refkey4ai>DISTASIX2020X2130XR</xocs:refkey4ai>
         <xocs:refkey5>DISTASIX2020X2130X2148XR</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2021-11-30T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2021-11-30T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Ltd. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-10-13T00:22:53.581Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type>
         <xocs:funding-source-document source-document-type="pii">S1359644620303792</xocs:funding-source-document>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Fondazione ‘Umberto Veronesi</xocs:funding-agency-matched-string>
            <xocs:funding-agency>Fondazione Umberto Veronesi</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004710</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/3175395/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding-text>Lucia De Rosa was awarded a PhD in biotechnology from the University of Naples ‘Federico II’ and is currently a research scientist at CNR, Naples. Her recent research activity was supported by the Fondazione ‘Umberto Veronesi’ (Milan, Italy) and is aimed at developing novel peptide-based molecules targeting the Axl receptor with therapeutic or diagnostic applications. Her main interests are in drug discovery, protein synthesis, and site-specific modification using chemical ligation methodologies. </xocs:funding-text>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(20)30379-2</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644620303792</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644620303792</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2020.09.022</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2020-11-30T17:00:06.888502Z</xocs:timestamp>
         <xocs:cover-date-start>2020-12-01</xocs:cover-date-start>
         <xocs:cover-date-end>2020-12-31</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/MAIN/application/pdf/40a6c8315d7273f0b5712f1266c19a17/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>3052531</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>19</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644620303792-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/PREVIEW/image/png/9163af164f5c39a6e2383a6bac457386/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>73719</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx1/DOWNSAMPLED/image/jpeg/9073c3f7334ec6f4d379015a7e395b39/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3303</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>89</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx2/DOWNSAMPLED/image/jpeg/0de00c02997327929fa022398333edc0/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3154</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>65</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx3/DOWNSAMPLED/image/jpeg/632e817f73e59dbb781fec69a2793894/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4251</xocs:filesize>
               <xocs:pixel-height>102</xocs:pixel-height>
               <xocs:pixel-width>84</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr1/DOWNSAMPLED/image/jpeg/ef4cd96b1eddb296f1b943b298a7413d/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>87624</xocs:filesize>
               <xocs:pixel-height>518</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr2/DOWNSAMPLED/image/jpeg/0df8946f1a97f4b7f8e1ae6699396a4c/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>68419</xocs:filesize>
               <xocs:pixel-height>598</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr3/DOWNSAMPLED/image/jpeg/b3294b2b31e5b65603925a0b726b7282/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>101523</xocs:filesize>
               <xocs:pixel-height>685</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr4/DOWNSAMPLED/image/jpeg/66b165428552eeca15964b8cf6cefdc5/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>109631</xocs:filesize>
               <xocs:pixel-height>745</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr5/DOWNSAMPLED/image/jpeg/966384836a625df7863a23a0f05c3ab4/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>85838</xocs:filesize>
               <xocs:pixel-height>681</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr6/DOWNSAMPLED/image/jpeg/452eb1ad8450889a235750a2f123a6e4/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>95525</xocs:filesize>
               <xocs:pixel-height>515</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr7/DOWNSAMPLED/image/jpeg/f4141868887686c46fdb77e1fff8ae5f/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>61185</xocs:filesize>
               <xocs:pixel-height>518</xocs:pixel-height>
               <xocs:pixel-width>885</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx1/THUMBNAIL/image/gif/83494cf07fa27c7fab6f77c86f17f6fb/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>24424</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx2/THUMBNAIL/image/gif/e5df1154bcb74e1f774d64881cbc104f/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14722</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>105</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx3/THUMBNAIL/image/gif/a5880cc3abe0a9b98007355671ca4b7a/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17773</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>134</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr1/THUMBNAIL/image/gif/ce9f719067f95aac1b34e692c0aefe5f/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9365</xocs:filesize>
               <xocs:pixel-height>136</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr2/THUMBNAIL/image/gif/dbbd8a4a48b5ee56eb7288763bfdf1f0/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7009</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr3/THUMBNAIL/image/gif/c89278593bfa3c2282b24fc6454e459c/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9196</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>200</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr4/THUMBNAIL/image/gif/d661606983a25e5cff5b93d3722e976c/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8847</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>184</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr5/THUMBNAIL/image/gif/a9bdec88a309eeff1fa9bceed5b00d3d/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7924</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>201</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr6/THUMBNAIL/image/gif/21944512ca4f3fb67ddbc2bfc8c77d16/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6784</xocs:filesize>
               <xocs:pixel-height>135</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr7/THUMBNAIL/image/gif/85d9f66410fba0729c2f737d9307d1bf/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6666</xocs:filesize>
               <xocs:pixel-height>128</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx1/HIGHRES/image/jpeg/a575e063cfa49a9376830b5b653f1f76/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37416</xocs:filesize>
               <xocs:pixel-height>344</xocs:pixel-height>
               <xocs:pixel-width>394</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx2/HIGHRES/image/jpeg/e69fd5129d394b7c4045d6814c38e705/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33522</xocs:filesize>
               <xocs:pixel-height>453</xocs:pixel-height>
               <xocs:pixel-width>292</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/fx3/HIGHRES/image/jpeg/4081da8c563ad9af14c8322ad2e7906f/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>47164</xocs:filesize>
               <xocs:pixel-height>453</xocs:pixel-height>
               <xocs:pixel-width>372</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr1/HIGHRES/image/jpeg/27d4e4c5791f3acedd48dccc1c63b601/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>841662</xocs:filesize>
               <xocs:pixel-height>2293</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr2/HIGHRES/image/jpeg/4746571c03b8d4580581dfafed0847f5/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>616212</xocs:filesize>
               <xocs:pixel-height>2648</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr3/HIGHRES/image/jpeg/140631a447739076e9682e75307970f6/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>826322</xocs:filesize>
               <xocs:pixel-height>3036</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr4/HIGHRES/image/jpeg/ba70b873d224dc67287962e8a927a5bc/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>933771</xocs:filesize>
               <xocs:pixel-height>3302</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr5/HIGHRES/image/jpeg/2dd06bbb56f070aabc79b01677fdbff6/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>856318</xocs:filesize>
               <xocs:pixel-height>3017</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr6/HIGHRES/image/jpeg/c739aff596c87051921c887f8a2c1050/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>799704</xocs:filesize>
               <xocs:pixel-height>2280</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620303792-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620303792/gr7/HIGHRES/image/jpeg/f8b1b1a631a77f3adc98f9237bd0906f/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>504369</xocs:filesize>
               <xocs:pixel-height>2292</xocs:pixel-height>
               <xocs:pixel-width>3917</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.5" xml:lang="en" docsubtype="rev">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>2786</aid>
            <ce:pii>S1359-6446(20)30379-2</ce:pii>
            <ce:doi>10.1016/j.drudis.2020.09.022</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Ltd</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spar0005" view="all">
                     <ce:bold>(a)</ce:bold> Structural organization of the Axl receptor before and after growth arrest-specific protein 6 (Gas6) binding. Axl shows an ecto-domain comprising two Immunoglobulin-like (Ig) domains and two fibronectin type III (FNIII) repeats. This portion is connected, through a trans-membrane region, to the intracellular kinase domain, in which are highlighted the amino acidic sequence KWIAIES and the Y779, Y821, Y866 residues, both responsible for complete Axl activation. Soluble Gas6 comprises an N-terminal ɤ carboxyglutamic acid (GLA) domain involved in the Ca<ce:sup loc="post">2+</ce:sup>-dependent binding to phosphatidylserine (PtdSer) units on the outer side of apoptotic cells and enveloped viruses. A thrombin-sensitive loop region (TSR) connects the GLA domain to the four epidermal growth factor (EGF)-like repeats, followed by the C-terminal sex hormone-binding globulin (SHBG)-like domain, in which the laminin G1 (LG1) domain establishes contacts with Axl Ig domains. Under inflammatory stimuli, the soluble form of Axl (sAxl) is generated from the monomeric receptor by ADAM10/17 cleavage at the amino acidic interface between FNIII-2 and the trans-membrane region. Asn 36 and Asn 150 and 191 are Axl putative glycosylation site in the Ig1 and Ig2 domains, respectively. <ce:bold>(b)</ce:bold> Relevant signaling pathways activated downstream of Axl/Gas6 interaction. Phosphorylated Tyr821 mediates binding to the p85α and p85β subunits of phosphatidylinositol-3-kinase (PI3K), activating the protein kinase B (AKT)-dependent pathway, enabling cell survival. It also recruits growth factor receptor-bound protein 2 (Grb2), promoting cell proliferation via mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling. Another survival pathway involves the activation of the nuclear factor kappa light chain enhancer of activated B cells (NF-κB) complex via PI3K/AKT signaling. NF-κB increases the expression of antiapoptotic proteins and, in the case of sepsis, avoids the alteration of endothelium tight junctions, inhibiting vascular endothelial hyperpermeability.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0005" role="short">Figure 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S1359644620303792/gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spar0010" view="all">Axl signaling activated in a breast cancer cell. The Axl receptor can operate also through the establishment of crosstalk axes with other receptor tyrosine kinases (RTKs). In breast cancer cells, Axl can bypass ligand binding, cross-talking with human epidermal growth factor receptor 2 (HER2). In this case, the receptor physically interacts with HER2, triggering the epithelial-to-mesenchymal transition (EMT) and tumor growth and metastases. Upon binding its ligand, growth arrest-specific protein 6 (Gas6), Axl enhances the expression and activity of matrix metalloproteinase 9 (MMP-9), engaging cell invasion and improving tumor metastatic spread.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0010" role="short">Figure 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S1359644620303792/gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0015">
               <ce:label>Figure 3</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="spar0015" view="all">Axl/growth arrest-specific protein 6 (Gas6) signaling in microglia innate immune system cells. Microglial cell stimulation involves the activation of Toll-like receptor (TLR) signaling, that, in turn, enhances proinflammatory cytokine secretion (red dots). Cytokine release upregulates Axl expression via type I interferon receptor signaling. Upon Gas6 binding, activated Axl induces intracellular pathways that work through a negative feedback loop involving the activation of suppressor of cytokine signaling -1 and -3 (SOSC1 and SOCS3), followed by the inactivation of TLR activity and cytokine receptor cascades. This results in the dampening of inflammatory responses. In the inflammation process that has been triggered by microglia activation, Axl receptor shedding increases, leading to high plasma levels of its soluble form, sAxl, which acts as a decoy receptor, sequestering soluble Gas6 and subtracting it from the full-length Axl on the cell surface. In this inflammatory environment derived from activated microglial cells, oligodendrocytes undergo apoptosis. The accumulation of cellular debris, together with the diminished ability to clear them because of the decreased activity of Axl/Gas6 signaling, causes demyelination of axon fibers in the central nervous system (CNS) and the onset of lesions in multiple sclerosis (MS).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0015" role="short">Figure 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S1359644620303792/gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0020">
               <ce:label>Figure 4</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="spar0020" view="all">Zika virus (ZIKV) infection mechanism in Sertoli cells mediated by the Axl/growth arrest-specific protein 6 (Gas6) axis. Viral entry occurs through Gas6 N-terminal ɤ carboxyglutamic acid (GLA) domain binding to phosphatidylserine (PtdSer) residues exposed on the virus envelope. Virus particles are internalized via clathrin-mediated endocytosis. During entry, the ZIKV/Gas6 complex activates the Axl kinase domain, which facilitates infection. Activated Axl interacts with the subunit 1 of the α/β interferon receptor (IFNAR1), promoting the autophosphorylation of signal transducer and activator of transcription 1 (STAT1) that translocates into the nucleus. This induces the expression of suppressor of cytokine signaling -1 and -3 (SOSC1 and SOCS3) and the inactivation of Toll-like receptors, ending in the suppression of type I IFN expression that facilitates viral replication in the host cell.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0020" role="short">Figure 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S1359644620303792/gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0025">
               <ce:label>Figure 5</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="spar0025" view="all">Schematic overview of the different approaches developed to target the Axl/growth arrest-specific protein 6 (Gas6) system. Tyrosine kinase (TK) inhibitors, non-TK inhibitors, antibodies (Ab), Ab-drug conjugates (ADC), decoy receptors, nucleotide aptamers, and cell-based systems are indicated. Abbreviations: GLA, γ carboxyglutamic acid domain; FNIII, fibronectin type III repeats; Ig, immunoglobulin-like domains; LG, laminin G repeats; ScFv, single-chain variable fragment.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0025" role="short">Figure 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S1359644620303792/gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0030">
               <ce:label>Figure 6</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="spar0030" view="all">Chemical structures and average masses of the small organic molecules developed to target the Axl/growth arrest-specific protein 6 (Gas6) molecular system.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0030" role="short">Figure 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S1359644620303792/gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0035">
               <ce:label>Figure I</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="spar0035" view="all">X-ray structure of the complex Axl-Gas6. Protein domains are colored in cyan (Gas6-LG1), blue (Gas6-LG2), yellow (Axl-IG1) and red (Axl-IG2).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0035" role="short">Figure I</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S1359644620303792/gr7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0005" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table I</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="spar0040" view="all">Structural information on Axl/Gas</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0040" role="short">Table I</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <colspec colname="col5"/></colspec>
                  <colspec colname="col6"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Molecule A (residues)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Molecule B (residues)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Method</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Resolution (Å)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Protein Data Bank</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Gas6 (261-678)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X-ray</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1H30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0005" refid="bib0890">[178]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Gas6 (261-678)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl (26-220)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X-ray</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2C5D</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0010" refid="bib0100">[20]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Gas6 (278-678)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl (26-220)<sup loc="post">a</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X-ray</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4RA0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0015" refid="bib0720">[144]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Gas6 (281-675)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl (27-128)<sup loc="post">b</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X-ray</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5VXZ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0020" refid="bib0725">[145]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Axl (514-818)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X-ray</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.84</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5U6B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0025" refid="bib0885">[177]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spar0045" view="all">
                     <ce:sup loc="post">a</ce:sup>The following mutations are present: G32S, D87<ce:hsp sp="0.25"/></ce:hsp>G, V92A, and G127R.</ce:simple-para>
                  <ce:simple-para id="spar0050" view="all">
                     <ce:sup loc="post">b</ce:sup>The following mutations are present: G32S, A72<ce:hsp sp="0.25"/></ce:hsp>V, D87<ce:hsp sp="0.25"/></ce:hsp>G, V92A, and G127R.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0010" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="spar0055" view="all">Axl/Gas6 targeting molecules in preclinical and clinical development<ce:cross-refs id="crfs0005" refid="tblfn0005 tblfn0010">
                        <ce:sup loc="post">a,b</ce:sup>
                     </ce:cross-refs>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0045" role="short">Table 1</ce:alt-text>
               <tgroup cols="5">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <colspec colname="col5"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Molecule</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Main target(s)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Number of clinical trials and progression stage<cross-ref id="crf0030" refid="tblfn0015">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pathological conditions under evaluation in clinical trials<cross-ref id="crf0035" refid="tblfn0020">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Tyrosine kinase inhibitors</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Bemcentinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AML, myelodysplastic syndrome, TNBC, inflammatory breast cancer, lung cancer metastatic, NSCLC, solid tumors, adenocarcinoma of lung, cancer of pancreas, brain and CNS tumors, malignant mesothelioma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0040" refid="bib0465">[93]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">2D08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0045" refid="bib0535">[107]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">TP-0903</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl, Mer, Tyro3, Aurora, Jak2, Alk, Abl, and Check1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic lymphocytic leukemia, small lymphocytic lymphoma, advanced solid tumors, NSCLC, CRC, recurrent ovarian carcinoma, melanoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0050" refid="bib0780">[156]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">eSM119</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aurora A, Axl, Mer, Src, Flt3, and Ret</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0055" refid="bib0470">[94]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">eSM134</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl, Flt3, Ret, and Aurora A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0060" refid="bib0470">[94]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">DP-3975</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0065" refid="bib0525">[105]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">DS-1205b</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0070" refid="bib0530">[106]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">DS-1205c</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 studies, Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NSCLC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0075" refid="bib0530">[106]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">SLC-391</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study, Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0080" refid="bib0785">[157]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">9im</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl and Mer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0085" refid="bib0475">[95]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">8i</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl and Flt3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0090" refid="bib0790">[158]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">NA80<hsp sp="0.25"/></hsp>×<hsp sp="0.25"/></hsp>1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Src and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0095" refid="bib0540">[108]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">SGI-7079</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl, Mer, Tyro3, Syk, VEGFR1, Flt3, Jak2, TrkA/B, PDGFRb, and Ret</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0100" refid="bib0020">[4]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">SNS-314</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aurora</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study, Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0105" refid="bib0795">[159]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Crizotinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met and Alk</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Approved for treatment of NSCLC; 154 studies, Phase I–IV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inflammatory myofibroblastic tumor, lobular breast carcinoma, gastric cancer, hematological cancers, uveal melanoma, castration-resistant prostate cancer, endometrial cancer, systemic anaplastic large-cell lymphoma, glioblastoma multiforme of cerebellum, neurofibromatosis 2, progressive vestibular schwannoma, kidney cancer, urothelial cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0110" refid="bib0550">[110]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Bosutinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl, Src, and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Approved for treatment of chronic myelogenous leukemia; 60 studies, Phase I–IV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NSCLC, mesothelioma, bladder cancer, ovarian cancer, peritoneal cancer, thymus cancer, uterine cervical cancer, glioblastoma, pancreatic cancer, breast cancer, CRC, cholangiocarcinoma, and others</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0115" refid="bib0540">[108]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Gilteritinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Flt3 and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Approved for treatment of relapsed or refractory acute myeloid leukemia; 26 studies, Phase I–III</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myelodysplastic syndrome, advanced solid tumors, AML, NSCLC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0120" refid="bib0555">[111]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">S49076</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met, Axl, Mer, and FGFR1/2/3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0125" refid="bib0800">[160]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">BPI-9016M</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 studies, Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NSCLC, solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0130" refid="bib0805">[161]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">INCB081776</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study, Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0135" refid="bib0810">[162]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Amuvatinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Kit and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SCLC, solid tumors, lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0140" refid="bib0815">[163]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Sunitinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR2 and PDGFRα</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Approved for treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors; 603 studies, Phase I–IV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Type B3 thymoma, thymic carcinoma, osteosarcoma, soft tissue sarcoma, cholangiocarcinoma, urinary tract urothelial carcinoma, glioblastoma multiforme, CRC, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, neuroendocrine tumors, breast cancer, and others</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0145" refid="bib0560">[112]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">UNC2025</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer and Flt3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0150" refid="bib0820">[164]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">UNC569</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0155" refid="bib0825">[165]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">UNC1062</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0160" refid="bib0830">[166]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">UNC1666</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer and Flt3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0165" refid="bib0835">[167]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">BMS-777607</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met, Axl, Mst1r, and Tyro3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced or metastatic solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0170" refid="bib0565">[113]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Cabozantinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR2, Flt3, Met, Kit, Ret, Axl, and Tie</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Approved for treatment of hepatocellular carcinoma, advanced renal cell carcinoma and medullary thyroid cancer; 163 studies, Phase I–IV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cervical cancer, urothelial carcinoma, salivary gland cancer, plexiform neurofibromas, bile duct cancer, intrahepatic cholangiocarcinoma, cholangiocarcinoma of extrahepatic bile duct, prostate cancer, gastric adenocarcinoma, gastroesophageal cancer, bladder carcinoma, neuroendocrine tumors, melanoma, and others</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0175" refid="bib0545">[109]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Merestinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met, Mst1r, Axl, Mer, Ddr1, and Tie1/2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10 Studies, Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Biliary tract carcinoma, cholangiocarcinoma, gall bladder carcinoma, solid tumor, non-Hodgkin’s lymphoma, NSCLC, adult AML, CRC, mantle cell lymphoma, pancreatic cancer, breast cancer, and others</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0180" refid="bib0840">[168]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Glesatinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met and VEGFRs, Tie, and Mst1r</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NSCLC, advanced malignancies</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0185" refid="bib0845">[169]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Sitravatinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl, EphA, Mer, VEGFRs, Flt3, Kit, Ddr, and TrkA/B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12 studies, Phase I–III</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced cancer, liposarcoma, head and neck squamous cell carcinoma, mouth squamous cell carcinoma, squamous cell carcinoma of oral cavity, TNBC, breast cancer, urothelial carcinoma, nonsquamous NSCLC, urothelial carcinoma, clear cell RCC, HCC, gastric/gastroesophageal junction cancer, and others</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0190" refid="bib0850">[170]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">NPS-1034</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0195" refid="bib0855">[171]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Rebastinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl1, Flt3, VEGFR2, Tie2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer, locally advanced or metastatic solid tumor, CML</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0200" refid="bib0860">[172]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Foretinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Met, VEGFR2/3, Tie2, and Ron</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lung cancer, HCC, breast cancer, head and neck squamous cell cancer, RCC, gastric cancer, lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0205" refid="bib0865">[173]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">ONO-7475</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 studies, Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute leukemia myelodysplastic syndromes, advanced or metastatic solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0210" refid="bib0870">[174]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">ONO-9330547</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0215" refid="bib0875">[175]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">LDC1267</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tyro3, Axl and Mer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0220" refid="bib0595">[119]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">RXDX-106</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tyro3, Axl, Mer, Met, and Ron</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study, early Phase I (terminated)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced or metastatic solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0225" refid="bib0880">[176]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Macrocyclic compound 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mer and Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0230" refid="bib0885">[177]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Clicked macrocycle</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0235" refid="bib0520">[104]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Small nontyrosine kinase inhibitors</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Warfarin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Gas6 GLA domain (indirect action)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study out of 767 studies exploring warfarin as Axl inhibitor, early Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pancreatic cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0240" refid="bib0585">[117]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">RU301</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">Axl-Ig1/Gas6-LG1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0245" refid="bib0605">[121]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">RU302</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Aptamers</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">GL21.T</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">AXL-ECD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0250" refid="bib0610">[122]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">AXL-APTAMER</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0255" refid="bib0620">[124]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Monoclonal antibodies</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">YW327.6S2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AX-ECD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0260" refid="bib0640">[128]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">DAXL-88</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AXL-ECD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0265" refid="bib0645">[129]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">3G9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl- Ig1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0270" refid="bib0650">[130]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">8B5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl- Ig1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">12A11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl- FNIII1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">D9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AXL-ECD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0275" refid="bib0660">[132]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">E8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AXL-ECD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">MAb173</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl-FNIII1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0280" refid="bib0655">[131]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">GMAB1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Gas6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0285" refid="bib0710">[142]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">CNTO300</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Gas6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0290" refid="bib0715">[143]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Antibody–drug conjugates</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Enapotamab vedotin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl- Ig1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study, Phase II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ovarian cancer, cervical cancer, endometrial cancer, NSCLC, thyroid cancer, melanoma, sarcoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0295" refid="bib0670">[134]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">BA3011</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl-ECD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Solid tumor, NSCLC, pancreatic cancer, melanoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0300" refid="bib0680">[136]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Decoy receptors</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">AVB-S6-500</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Gas6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7 studies, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clear cell RCC, fallopian tube carcinoma, primary peritoneal carcinoma, ovarian cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0305" refid="bib0720">[144]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Recombinant Gas6</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">rGas6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0310" refid="bib0735">[147]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left" namest="col1" nameend="col5">Engineered T cells</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">CAR-T CCT301</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Axl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 study, Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RCC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0010" refid="bib0765 bib0770">[153,154]</cross-refs>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tblfn0005">
                  <ce:label>a</ce:label>
                  <ce:note-para id="npar0005" view="all">Abbreviations: Alk, anaplastic lymphoma kinase; Check1, checkpoint kinase 1; Ddr1, discoidin domain receptor tyrosine kinase 1; EphA, erythropoietin-producing human hepatocellular receptor A; Flt3, fms-like tyrosine kinase 3; Jak2, Janus kinase 2; Mst1r, macrophage-stimulating protein receptor; Syk, spleen tyrosine kinase; Trk, tropomyosin receptor kinase.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0010">
                  <ce:label>b</ce:label>
                  <ce:note-para id="npar0010" view="all">Clinical trial data were retrieved from <ce:inter-ref id="intr0005" xlink:href="http://www.clinicaltrials.gov" xlink:type="simple">www.clinicaltrials.gov</ce:inter-ref>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0015">
                  <ce:label>c</ce:label>
                  <ce:note-para id="npar0015" view="all">The total number of clinical trials was updated during April 2020.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0020">
                  <ce:label>d</ce:label>
                  <ce:note-para id="npar0020" view="all">The detailed type and list of the pathologic conditions explored in the clinical trials can be found at <ce:inter-ref id="intr0010" xlink:href="http://www.clinicaltrials.gov" xlink:type="simple">www.clinicaltrials.gov</ce:inter-ref>.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:textbox id="tb0005">
               <ce:label>Box 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="spar0060" view="all">A structural view of Axl/Gas6 proteins</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0050" role="short">Box 1</ce:alt-text>
               <ce:textbox-body>
                  <ce:sections>
                     <ce:para id="par0005" view="all">Axl and Gas6 proteins have been only partially characterized at high resolution (<ce:cross-ref id="crf0315" refid="tbl0005">Table I</ce:cross-ref>
                        <ce:float-anchor refid="tbl0005"/></ce:float-anchor>). Even though their domains show a sequence homology to other already characterized molecules, Axl and Gas6 present some specificities that warrant a closer structural look, such as the role of the Gas6-Gla domain (involved in the interaction with cellular exposed phosphatidylserine residues) in Axl activation or the orientation of Axl extracellular domains in receptor dimerization.</ce:para>
                     <ce:para id="par0010" view="all">The Gas6 protein comprises a Gla domain, four EGF-like domains, and two laminin G-like (LG) domains. Structural information is available only for the LG domains. They have been described in the free form or complexed to the Axl receptor.</ce:para>
                     <ce:para id="par0015" view="all">The Axl receptor comprises an extracellular region of two Ig-like (IG) and two FNIII domains, a transmembrane region and an intracellular TK domain. The structure of the IG domains has been reported only in complex with Gas6. Information on FNIII motifs is lacking even though the NMR structure of the related Mer-FNIII domain has been deposited in the Protein Data Bank (2dbj.pdb). Different from the TK domain of the related Tyro3 and Mer proteins, the Axl-TK structure in free form remains elusive, probably because of a major flexibility and minor stability issues <ce:cross-ref id="crf0320" refid="bib0885">[177]</ce:cross-ref>. However, it was recently crystallized in complex with a macrocyclic inhibitor. Interestingly, the Axl-TK domain adopts two conformational states in the complex, including an active conformation that is different from the previous Tyro3 and Mer kinase structures, which describe the enzyme inactive state.</ce:para>
                     <ce:para id="par0020" view="all">The structure of the Axl/Gas6 complex involving Gas6 LG1-LG2 and Axl IG1-IG2 was solved in 2006 (<ce:cross-ref id="crf0323" refid="fig0035">Fig. I</ce:cross-ref>
                        <ce:float-anchor refid="fig0035"/></ce:float-anchor>). The complex presents a 2:2 stoichiometry in which Gas6/Gas6 or Axl/Axl direct contacts are absent and only LG1 of Gas6 is involved in Axl binding, interacting with both the Axl IG1 and IG2 domains. The Gas6/Axl complex shows two distinct contact regions, both of which are required for receptor activation. The high-affinity site (LG1-IG1) involves a surface area of 2366<ce:hsp sp="0.25"/></ce:hsp>Å<ce:sup loc="post">2</ce:sup>, whereas the low-affinity site (LG1-IG2) buries 765<ce:hsp sp="0.25"/></ce:hsp>Å<ce:sup loc="post">2</ce:sup>. Both interaction sites present the juxtaposition of edge β-strands.</ce:para>
                     <ce:para id="par0025" view="all">The structures of Gas6-LG domains in complex with Axl decoy receptors (MYD1 and MYD1-72) have also been reported, which were obtained by introducing specific mutations in Axl-Ig1. Unexpectedly, decoy receptors induced a conformational change (restructuring) in helix A of Gas6, which is mainly disordered in Axl/Gas6, stabilizing the complex.</ce:para>
                  </ce:sections>
               </ce:textbox-body>
            </ce:textbox>
         </ce:floats>
         <head>
            <ce:dochead id="doh0005">
               <ce:textfn>Review</ce:textfn>
               <ce:dochead id="doh0010">
                  <ce:textfn>Keynote</ce:textfn>
               </ce:dochead>
            </ce:dochead>
            <ce:title id="tit0005">Therapeutic aspects of the Axl/Gas6 molecular system</ce:title>
            <ce:author-group id="aug0005">
               <ce:author id="aut0005" biographyid="vt0005" author-id="S1359644620303792-48e33004dca7a3abbc1496d52e48690f">
                  <ce:given-name>Rossella</ce:given-name>
                  <ce:surname>Di Stasi</ce:surname>
                  <ce:cross-ref id="crf0325" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0010" biographyid="vt0010" author-id="S1359644620303792-5333db7af2f8d96ea3bfbb90207b84e9">
                  <ce:given-name>Lucia</ce:given-name>
                  <ce:surname>De Rosa</ce:surname>
                  <ce:cross-ref id="crf0330" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0015" biographyid="vt0015" orcid="0000-0002-2589-216X" author-id="S1359644620303792-31090409d37ba69dfe059f4bb4c8d94b">
                  <ce:given-name>Luca D.</ce:given-name>
                  <ce:surname>D’Andrea</ce:surname>
                  <ce:cross-ref id="crf0335" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0340" refid="cor0005">
                     <ce:sup loc="post">⁎</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff0005" affiliation-id="S1359644620303792-3e6f0a1b85e27611513f63c88a779780">
                  <ce:label>1</ce:label>
                  <ce:textfn>Istituto di Biostrutture e Bioimmagini, CNR, Via Mezzocannone 16, 80134 Napoli, Italy</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Istituto di Biostrutture e Bioimmagini</sa:organization>
                     <sa:organization>CNR</sa:organization>
                     <sa:address-line>Via Mezzocannone 16</sa:address-line>
                     <sa:city>Napoli</sa:city>
                     <sa:postal-code>80134</sa:postal-code>
                     <sa:country>Italy</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0010" affiliation-id="S1359644620303792-d7a56c673e06df481dd22b6ec2688acf">
                  <ce:label>2</ce:label>
                  <ce:textfn>Istituto di Biostrutture e Bioimmagini, CNR, Via Nizza 52, 10126 Torino, Italy</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Istituto di Biostrutture e Bioimmagini</sa:organization>
                     <sa:organization>CNR</sa:organization>
                     <sa:address-line>Via Nizza 52</sa:address-line>
                     <sa:city>Torino</sa:city>
                     <sa:postal-code>10126</sa:postal-code>
                     <sa:country>Italy</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor0005">
                  <ce:label>⁎</ce:label>
                  <ce:text>
                     <ce:italic>Corresponding author</ce:italic>.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            
            <ce:abstract id="abs0010" view="all" class="author"><ce:abstract-sec id="abst0010" view="all">
                  <ce:simple-para id="spar0070" view="all">Axl receptor tyrosine kinase (RTK) and its ligand, growth arrest-specific protein 6 (Gas6), are involved in several biological functions and participate in the development and progression of a range of malignancies and autoimmune disorders. In this review, we present this molecular system from a drug discovery perspective, highlighting its therapeutic implications and challenges that need to be addressed. We provide an update on Axl/Gas6 axis biology, exploring its role in fields ranging from angiogenesis, cancer development and metastasis, immune response and inflammation to viral infection. Finally, we summarize the molecules that have been developed to date to target the Axl/Gas6 molecular system for therapeutic and diagnostic applications.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract id="abs0015" class="teaser" view="all">
               <ce:section-title id="sect0010">Teaser</ce:section-title>
               <ce:abstract-sec id="abst0015" view="all">
                  <ce:simple-para id="spar0075" view="all">We provide an overview of Axl/Gas6 biology and pathology for insights for the development of novel drugs.</ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0005" role="introduction" view="all">
                  <ce:section-title id="sect0015">Introduction</ce:section-title>
                  <ce:para id="par0055" view="all">The Axl RTK and its ligand, Gas6, constitute an interesting therapeutic target that has recently gained much attention given their involvement in several pathologies. Axl and Gas6 regulate numerous cellular responses, such as proliferation, survival, adhesion, migration, autophagy, invasion, angiogenesis, platelet aggregation, and natural killer cell differentiation <ce:cross-ref id="crf0345" refid="bib0005">[1]</ce:cross-ref>. In addition, Axl is a potent negative regulator of innate immune responses <ce:cross-ref id="crf0350" refid="bib0010">[2]</ce:cross-ref>, thus protecting against an overactive inflammatory response. The Axl receptor is overexpressed in several cancers <ce:cross-ref id="crf0355" refid="bib0015">[3]</ce:cross-ref> and its expression level is often correlated with a poor prognosis or has been associated with cancer drug resistance <ce:cross-refs id="crfs0015" refid="bib0020 bib0025 bib0030 bib0035">[4–7]</ce:cross-refs>, highlighting its possible exploitation as biomarker <ce:cross-ref id="crf0360" refid="bib0040">[8]</ce:cross-ref>. Furthermore, Axl and Gas6 have a key role in the transition from cancer to metastasis promoting the epithelial-to-mesenchymal transition (EMT) <ce:cross-ref id="crf0365" refid="bib0045">[9]</ce:cross-ref>. Their capacity to regulate innate immune responses shed light on their role in autoimmune diseases, such as multiple sclerosis (MS) <ce:cross-refs id="crfs0020" refid="bib0050 bib0055">[10,11]</ce:cross-refs>. Finally, Axl and Gas6 are a key molecular system exploited by flaviviruses, such as Ebola (EBV) or Zika (ZIKV) viruses <ce:cross-refs id="crfs0025" refid="bib0060 bib0065">[12,13]</ce:cross-refs>. The Axl/Gas6 system is also involved in other pathological settings, such as fibrosis, as reviewed elsewhere <ce:cross-ref id="crf0370" refid="bib0070">[14]</ce:cross-ref>. The ability to modulate the activity of Axl/Gas6 axis with drugs or biological agents is crucial to find novel therapies for a range of diseases. So far, several inhibitors have been reported but effort is still needed remain to find molecules for use in the clinic. In this review, we emphasize the pleiotropic role of the Axl/Gas6 system by focusing on different pathology settings to encourage the drug discovery community to look for novel molecular tools that can interact with Axl/Gas6 or modulate their biological activity.</ce:para>
               </ce:section>
               <ce:section id="sec0010" view="all">
                  <ce:section-title id="sect0020">Axl/Gas6 axis: architecture and biology of the system</ce:section-title>
                  <ce:para id="par0060" view="all">The gene encoding the Axl receptor is highly conserved across species, it contains 20 exons and is located on chromosome 19q13.2. It encodes a polypeptide chain (Uniprot: P30530) of 100<ce:hsp sp="0.25"/></ce:hsp>kDa, although the mature protein shows a higher molecular weight because of post-translational modification events, such as glycosylation, phosphorylation, and ubiquitination <ce:cross-ref id="crf0375" refid="bib0075">[15]</ce:cross-ref>. <ce:italic>Axl</ce:italic> was first isolated in a screening for transforming genes performed in cells of patients with chronic myeloid leukemia (CML) <ce:cross-ref id="crf0380" refid="bib0080">[16]</ce:cross-ref>, even though it is ubiquitously expressed in several human cell types originating from hematopoietic, epithelial, and mesenchymal sources <ce:cross-refs id="crfs0030" refid="bib0050 bib0085">[10,17]</ce:cross-refs>. Axl is a RTK belonging to the Tyro, Axl and Mer (TAM) receptor family. TAM receptors are characterized by an extracellular domain constituted by two immunoglobulin-like (Ig-like) motifs and two fibronectin type III (FNIII) repeats. This portion is connected, through a transmembrane domain, to a highly conserved cytoplasmic domain that contains an hallmark signature sequence, KWIAIES in Axl, distinguishing the TAM receptors from all other known RTKs and having an important role in kinase domain activity (<ce:cross-ref id="crf0385" refid="fig0005">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig0005"/></ce:float-anchor>a) <ce:cross-refs id="crfs0035" refid="bib0085 bib0090">[17,18]</ce:cross-refs>. Although TAM receptors other than Axl also present an interesting biology, our focus here is on Axl/Gas6. Axl extracellular architecture recalls the organization of cell adhesion molecules, such as cadherins and neural cell adhesion molecules <ce:cross-refs id="crfs0040" refid="bib0075 bib0095">[15,19]</ce:cross-refs>. As with all RTKs, upon ligand binding, Axl dimerizes and the intracellular tyrosine kinase domain becomes activated <ce:cross-ref id="crf0390" refid="bib0100">[20]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0065" view="all">In 1995, Gas6 and protein S, two different vitamin K-dependent signaling glycoproteins, were identified as ligands for TAM receptors. Gas6 activates all three TAM receptors but exhibits the greatest binding affinity for Axl <ce:cross-ref id="crf0395" refid="bib0105">[21]</ce:cross-ref>. Protein S has been identified as a ligand only for the Tyro3 and Mer receptors, although recent studies showed that, in pathological contests, protein S can also bind and activate Axl <ce:cross-ref id="crf0400" refid="bib0110">[22]</ce:cross-ref>. Gas6 is a soluble glycoprotein of 75<ce:hsp sp="0.25"/></ce:hsp>kDa (Uniprot: Q14393) with a modular composition. It contains an amino terminal ɤ carboxyglutamic acid (GLA) domain that mediates, in a Ca<ce:sup loc="post">2+</ce:sup>-dependent manner, binding to phospholipid-containing membranes, including externalized negatively charged phosphatidylserine (PtdSer) on apoptotic cells (ACs) and enveloped viruses (<ce:cross-ref id="crf0405" refid="fig0005">Fig. 1</ce:cross-ref>a) <ce:cross-ref id="crf0410" refid="bib0115">[23]</ce:cross-ref>. The N-terminal GLA domain is followed by a thrombin-sensitive loop region and four epidermal growth factor-like (EGF) domains ending with a C-terminal unit comprising two laminin G repeats (LG1 and LG2) that together constitute the sex hormone-binding globulin-like domain (<ce:cross-ref id="crf0415" refid="fig0005">Fig. 1</ce:cross-ref>a). Gas6 is expressed at low levels in the liver and human plasma, but is widely expressed in other several tissues, such as in the heart, kidneys, intestine, and lungs tissues. It is also expressed in endothelial cells (ECs), vascular smooth muscle cells (VSMCs), bone marrow cells, and the central nervous system (CNS) <ce:cross-refs id="crfs0045" refid="bib0120 bib0125 bib0130 bib0135">[24–27]</ce:cross-refs>. Gas6 interacts with the extracellular domain of Axl, as demonstrated by the Z-ray structure of the complex (<ce:cross-ref id="crf0420" refid="tb0005">Box 1</ce:cross-ref>
                     <ce:float-anchor refid="tb0005"/></ce:float-anchor>), through its LG1 domain, and Axl glycosylation is not required for Gas6 binding <ce:cross-ref id="crf0425" refid="bib0100">[20]</ce:cross-ref>. Moreover, the Gas6 GLA domain is essential for Axl activation. In fact, the GLA-truncated version of the ligand is still able to bind Axl with the same affinity as the full-length Gas6, but it is unable to activate the receptor. Therefore, the GLA domain/PtdSer interaction has a key role in Axl activation <ce:cross-ref id="crf0430" refid="bib0115">[23]</ce:cross-ref>, even in AC-free contexts, such as those in which the PtdSer units are present on microparticles derived from blood cells <ce:cross-ref id="crf0435" refid="bib0140">[28]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0070" view="all">Upon Gas6 binding, Axl receptor undergoes homodimerization and <ce:italic>trans</ce:italic>-autophosphorylation in the kinase domain. Six phosphorylation sites have been identified in the Axl kinase domain. Tyr698, Tyr702, and Tyr703, considered the putative autophosphorylation sites, are responsible for Axl activation, whereas Tyr779, Tyr821, and Tyr866 are required for complete kinase functions. In fact, once phosphorylated, they are docking sites involved in the recruitment and phosphorylation of adaptor and effector binding proteins ultimately allowing the activation of downstream signaling cascades (<ce:cross-ref id="crf0440" refid="fig0005">Fig. 1</ce:cross-ref>b) <ce:cross-refs id="crfs0050" refid="bib0015 bib0145">[3,29]</ce:cross-refs>. In particular, Y821 mediates the interaction of Axl with signaling molecules including phospholipase Cɤ, phosphatidylinositol 3-kinase (PI3K), and growth factor receptor-bound protein 2 <ce:cross-refs id="crfs0055" refid="bib0150 bib0155">[30,31]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0075" view="all">Depending on the downstream pathway activated upon ligand binding, different cellular responses can be observed (<ce:cross-ref id="crf0445" refid="fig0005">Fig. 1</ce:cross-ref>b). Gas6/Axl interaction, activating the PI3K-AKT, ERK1/2, and MAPK intracellular pathways, promotes cell survival, growth, and proliferation <ce:cross-ref id="crf0450" refid="bib0160">[32]</ce:cross-ref>. In dendritic cells (DCs), Axl signaling acts to limit inflammatory responses by inducing the suppressor of cytokine signaling (SOCS) proteins, which in turn inhibit toll-like receptors (TLRs) and cytokine receptor signaling <ce:cross-ref id="crf0455" refid="bib0165">[33]</ce:cross-ref>. In a mouse model of sepsis, the Gas6/Axl axis is able to inhibit vascular endothelial hyperpermeability through the activation of the intracellular NF-κB signaling pathway, avoiding the alteration of endothelium tight junctions and exerting a protective effect on the endothelial barrier, the severe failure of which is associated with sepsis <ce:cross-ref id="crf0460" refid="bib0170">[34]</ce:cross-ref>. Axl/Gas6 signaling is particularly important in inflammatory settings, because proinflammatory agents upregulate the expression of Axl, specifically mediating the phagocytosis of ACs in inflammatory environments. This process is activated by Gas6 ligand binding, which, in turn, bridges the phagocyte-activated Axl receptor to the so-called ‘eat-me’ signal PtdSer on the target AC <ce:cross-ref id="crf0465" refid="bib0175">[35]</ce:cross-ref>. Phagocytosis of ACs and cellular debris is a crucial process necessary to avoid tissue necrosis and autoimmune responses. In fact, Axl-knockout mice show no obvious development defects at birth but the onset of autoimmune diseases and a multitude of other irregularities occur in adults <ce:cross-refs id="crfs0060" refid="bib0050 bib0180">[10,36]</ce:cross-refs>. Moreover, Axl signaling strongly contributes to AC clearance by macrophages during inflammation. In fact, inflammatory stimuli, correlated with the release of Interferon α (IFNα) and the TLR3 ligand poly(I:C), induce Axl expression in murine and human macrophages, promote Gas6/Axl binding, and increase the ability of macrophages to engulf ACs <ce:cross-ref id="crf0470" refid="bib0185">[37]</ce:cross-ref>. Finally, recent research reported that Axl is involved in the removal of apoptotic eosinophils to clear allergic airway inflammation, thus having a role in asthma <ce:cross-ref id="crf0475" refid="bib0190">[38]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0080" view="all">Axl is also present in a soluble form (sAxl) that is correlated with several biological dysfunctions. sAxl is released after cleavage by the metalloproteinases (MMPs) ADAM17 and ADAM10, which recognize an amino acidic sequence that occurs between the FNIII-2 domain and the transmembrane region (<ce:cross-ref id="crf0480" refid="fig0005">Fig. 1</ce:cross-ref>a) <ce:cross-refs id="crfs0065" refid="bib0195 bib0200">[39,40]</ce:cross-refs>. Circulating sAxl is able to capture Gas6, thus inhibiting full-length receptor activity <ce:cross-ref id="crf0485" refid="bib0205">[41]</ce:cross-ref>. sAxl has also been proposed as a promising biomarker. Staufer <ce:italic>et al.</ce:italic> demonstrated sAxl and Gas6 serum levels as diagnostic tool for advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) <ce:cross-ref id="crf0490" refid="bib0210">[42]</ce:cross-ref>. Additionally, sAxl is detectable at high levels in the plasma of patients with MS <ce:cross-ref id="crf0495" refid="bib0215">[43]</ce:cross-ref>. Thus, not only the axis formed by Gas6 and the full-length Axl receptor, but also the receptor soluble form could represent an appealing molecular system for drug development.</ce:para>
               </ce:section>
               <ce:section id="sec0015" view="all">
                  <ce:section-title id="sect0025">Axl/Gas6 proteins in angiogenesis, cancer development, and metastasis</ce:section-title>
                  <ce:para id="par0085" view="all">Axl expression is quiescent in adults, but its aberrant or ectopic expression is associated with human malignancies, including CML, breast cancer, melanoma, glioblastoma, and a variety of other tumor types <ce:cross-ref id="crf0500" refid="bib0075">[15]</ce:cross-ref>. The Axl/Gas6 axis is often correlated with patient poor prognosis (see Tables 1 and 2 in <ce:cross-ref id="crf0505" refid="bib0220">[44]</ce:cross-ref>). Axl/Gas6 signaling is also strongly associated with cancer growth, metastasis, and invasion. In these pathological contests, Gas6 is able to activate Axl in both an autocrine and paracrine manner and is considered a negative prognostic factor <ce:cross-ref id="crf0510" refid="bib0220">[44]</ce:cross-ref>. It has been demonstrated that Axl has a pivotal role in the EMT, a phenomenon that, when dysregulated, improves the cancer metastatic potential and represents an additional mechanism of drug resistance. EMT allows cells to detach from the primary tumor site and, migrating through the extracellular matrix, to intravasate into blood vessels, promoting metastases <ce:cross-ref id="crf0515" refid="bib0045">[9]</ce:cross-ref>. Increased Axl activity allows tumor cells to acquire a metastatic phenotype. In fact, genetic inactivation of Axl in mesenchymal tumor cells led to a decrease in the expression of specific mesenchymal markers, such as N-cadherin, and to increases in the expression of epithelial markers, such as E-cadherin, reducing tumor invasive potential <ce:cross-ref id="crf0520" refid="bib0045">[9]</ce:cross-ref>. Moreover, the activation of Axl downstream signaling pathways induces proinflammatory cytokine secretion, in turn stimulating the production of adhesion molecules and MMPs, facilitating cell detachment and migration. Once phosphorylated and activated, Axl stimulates the expression and activity of the MMP-9 promoting the breakdown of the extracellular matrix, which is a process closely associated with metastatic spread <ce:cross-ref id="crf0525" refid="bib0225">[45]</ce:cross-ref>. Furthermore, the use of Axl inhibitors in the treatment of murine breast tumors reduced proinflammatory cytokine secretion and metastases as well as blocking angiogenesis <ce:italic>in vivo</ce:italic> 
                     <ce:cross-ref id="crf0530" refid="bib0230">[46]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0090" view="all">Axl signaling can regulate both tumorigenesis and the associated neovascularization. Axl-knockdown studies demonstrated that Axl expression triggered tumor growth in a human breast cancer xenograft model and was prominent in the vasculature, which promotes angiogenesis. Given that angiogenesis supports and nourishes tumor growth, it is evident that Axl signaling is involved in both processes. Axl modulates EC functions by altering their gene expression and encouraging the morphological differentiation correlated with the acquisition of an invasive phenotype promoting the angiogenic switch observed in pathological settings. Although Axl and Gas6 are coexpressed in ECs and silencing of either gene impairs their motility, proliferation and tube formation <ce:italic>in vitro</ce:italic> 
                     <ce:cross-ref id="crf0535" refid="bib0235">[47]</ce:cross-ref>, Gallicchio <ce:italic>et al.</ce:italic> demonstrated that Gas6 antagonizes Vascular endothelial growth factor receptor 2 (VEGFR2)-dependent angiogenic processes <ce:cross-ref id="crf0540" refid="bib0240">[48]</ce:cross-ref>. In immunoprecipitation experiments, VEGFR2 autophosphorylation was inhibited in ECs preincubated with Gas6, but this result was not a consequence of Gas6 binding to VEGFR2. Gallicchio <ce:italic>et al.</ce:italic> speculated that, because the Gas6/Axl axis induces the activation of Src homology region 2 domain-containing phosphatase-2 (SHP2), through its association with the Axl kinase domain, SHP2 could determine VEGFR2 dephosphorylation and inactivation <ce:cross-ref id="crf0545" refid="bib0240">[48]</ce:cross-ref>. However, the effects observed in an <ce:italic>in vivo</ce:italic> SCID mouse model of human angiogenesis of Axl silencing were similar to those produced in VEGFR2 knockdown; thus, further research on Gas6-mediated VEGFR2 inhibition and Axl-silencing effect is required <ce:cross-ref id="crf0550" refid="bib0235">[47]</ce:cross-ref>. Axl and Gas6 are prominently expressed in the vasculature and can also operate their signaling in physiological contests, ensuring EC survival in addition to promoting remodeling of the endothelium barrier in response to wound healing and vessel damage <ce:cross-ref id="crf0555" refid="bib0075">[15]</ce:cross-ref>. Several vascular cell types expressing Axl and Gas6, including ECs, VSMCs, pericytes, fibroblasts, and myofibroblasts, contribute to vascular remodeling occurring through cellular migration, proliferation, and survival. For each of these processes, Axl and Gas6 have been shown to have a fundamental role <ce:cross-ref id="crf0560" refid="bib0245">[49]</ce:cross-ref>. Axl/Gas6 signaling in cancer can also be regulated by hypoxic stress within the tumor microenvironment. Hypoxia represents the most well-known hallmark for all solid tumors because it is associated with tumor angiogenesis, tumor progression, metastasis, and drug resistance. In recent studies, Axl was identified as a direct transcriptional target of hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2) in hypoxic HCC cells, where it mediates the prometastatic behavior of HIF signaling <ce:cross-ref id="crf0565" refid="bib0220">[44]</ce:cross-ref>. This evidence was confirmed by immunohistochemical staining of tumor tissues where the coexpression of Axl, Gas6, and HIF-1 was demonstrated, supporting the hypothesis that hypoxia is a stimulus for Axl upregulation in human cancers <ce:cross-ref id="crf0570" refid="bib0250">[50]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0095" view="all">The high levels of Axl expression represent a common feature of drug-resistant cancers <ce:cross-ref id="crf0575" refid="bib0255">[51]</ce:cross-ref> and correlate with refractoriness to different classes of inhibitors and poor prognosis for patients. A mechanism through which Axl induces resistance to antitumor agents is related to the establishment of crosstalk axes between different RTKs, including Tyro3 and Mer <ce:cross-ref id="crf0580" refid="bib0165">[33]</ce:cross-ref>, epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (HGFR), platelet-derived growth factor receptor (PDGFR), and VEGFR2 <ce:cross-ref id="crf0585" refid="bib0260">[52]</ce:cross-ref>. In a drug-resistant cancer, the activation of a secondary RTK can reactivate downstream pathways while the primary tyrosine kinase is still inhibited, leading to cancer progression also in the presence of the inhibitor itself. This is the case in which Axl activation occurs in EGFR inhibitor-resistant cancers, bypassing the inhibitor effect <ce:cross-refs id="crfs0070" refid="bib0050 bib0265">[10,53]</ce:cross-refs>. Axl is broadly expressed in breast cancer <ce:cross-ref id="crf0590" refid="bib0045">[9]</ce:cross-ref> and can also be activated in absence of its ligand Gas6 by cooperating with other transmembrane RTKs. For example, in HER2-positive breast cancer, bypassing Gas6 binding, Axl physically interacts with HER2, leading to its transphosphorylation and activation (<ce:cross-ref id="crf0595" refid="fig0010">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig0010"/></ce:float-anchor>). This mechanism promotes and triggers tumor cell invasion <ce:cross-ref id="crf0600" refid="bib0260">[52]</ce:cross-ref>. Ligand-independent heterotypic receptor dimerization of Axl has also been reported with IL-15R alpha in immortalized and primary fibroblasts <ce:cross-ref id="crf0605" refid="bib0270">[54]</ce:cross-ref>. Axl heterodimerization can occur with other transmembrane receptors in multiple pathological and physiological contexts <ce:cross-ref id="crf0610" refid="bib0260">[52]</ce:cross-ref>, creating a intricate network of receptor interactions and requiring complicated solutions to be adopted, in case of malignancies, to stem their advance. A strategy to affect tumor growth and metastasis could involve the co-targeting of Axl and other receptors involved in crosstalk mechanisms.</ce:para>
                  <ce:para id="par0100" view="all">In cancer progression, epigenetic changes can also occur, allowing an escape from normal cellular mechanisms. In this context, the role of miRNA regulating Axl expression was first reported by Mudduluru <ce:italic>et al.</ce:italic> in 2011. In their study, they demonstrated that two miRNAs targeting the 3′-untranslated region (UTR) of <ce:italic>Axl</ce:italic> can inhibit the expression and biological responses of the Axl receptor, such as migration, invasion, and metastasis of cancer cells, supporting the concept that such a class of small endogenous RNAs can function as tumor suppressors <ce:cross-ref id="crf0615" refid="bib0275">[55]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0105" view="all">Thus, Axl is a valid target for cancer therapy and diagnosis. Therapies based on the use of Axl inhibitors, especially in multitargeting approaches, would be useful to reduce both tumor growth and its metastatic potential.</ce:para>
               </ce:section>
               <ce:section id="sec0020" view="all">
                  <ce:section-title id="sect0030">Axl/Gas6 proteins in the regulation of immune response: roles in multiple sclerosis and other autoimmune diseases</ce:section-title>
                  <ce:para id="par0110" view="all">TAM receptors and their ligands have a fundamental role in regulating cell homeostasis and the inhibition of the innate inflammatory immune response, included those occurring in the CNS <ce:cross-ref id="crf0620" refid="bib0280">[56]</ce:cross-ref>. In particular, depending on the organ and cell type, Axl signaling regulates tissue repair and pro- and anti-inflammatory immune responses <ce:cross-ref id="crf0625" refid="bib0165">[33]</ce:cross-ref>. Axl loss-of-function enhances chronic inflammation and results in a multitude of autoimmune diseases that are caused by the failure to clear ACs and cell debris <ce:cross-ref id="crf0630" refid="bib0285">[57]</ce:cross-ref>. These chronic inflammatory pathologies include MS, systemic lupus erythematosus (SLE), Behçet’s disease (BD) <ce:cross-ref id="crf0635" refid="bib0290">[58]</ce:cross-ref>, rheumatoid arthritis (RH) <ce:cross-ref id="crf0640" refid="bib0295">[59]</ce:cross-ref>, sepsis <ce:cross-refs id="crfs0075" refid="bib0300 bib0305">[60,61]</ce:cross-refs>, systemic sclerosis (SS), and scleroderma spectrum disorders (SSD) <ce:cross-ref id="crf0645" refid="bib0310">[62]</ce:cross-ref>. In patients with SLE and BD, lower Gas6 and higher sAxl plasma concentrations have been reported compared with healthy individuals. In the case of RH, both Axl and Gas6 levels are significantly decreased in patients compared with healthy individuals <ce:cross-refs id="crfs0080" refid="bib0290 bib0295">[58,59]</ce:cross-refs>. In patients with sepsis, both Gas6 and sAxl levels are increased in circulation <ce:cross-refs id="crfs0085" refid="bib0300 bib0305">[60,61]</ce:cross-refs>. Dosing plasma levels of Gas6 and sAxl could also aid in the follow-up of patients with SS and SSD <ce:cross-ref id="crf0650" refid="bib0310">[62]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0115" view="all">Focusing on MS, Axl and its ligand Gas6 are expressed in several types of CNS cells, including microglia and oligodendrocytes (ODs), the myelin-producing cells, acting as important modulators of their survival and microglial phenotype <ce:cross-ref id="crf0655" refid="bib0315">[63]</ce:cross-ref>. Microglial cells are activated in response to any perturbation of CNS, such as in the case of pathogen injury (<ce:cross-ref id="crf0660" refid="fig0015">Fig. 3</ce:cross-ref>
                     <ce:float-anchor refid="fig0015"/></ce:float-anchor>). Following the production of proinflammatory cytokines, microglial cells are activated and involved in OD apoptosis and myelin degradation, a phenomenon that occurs at an early stage in the formation of a MS lesion and, consequently, in the onset of the pathology <ce:cross-ref id="crf0665" refid="bib0320">[64]</ce:cross-ref>. Axonal damage found in patients with MS correlates to the loss of their myelin sheath and demyelination is recognized as the most significant contributor to MS disease progression <ce:cross-ref id="crf0670" refid="bib0010">[2]</ce:cross-ref>. Stimulation of microglia cells activates TLR signaling pathways, enhancing proinflammatory cytokine secretion that, in turn, strongly upregulates Axl expression <ce:cross-refs id="crfs0090" refid="bib0010 bib0325">[2,65]</ce:cross-refs> through type I IFN signaling. This translates into SOCS1 and SOCS3 upregulation, which has a crucial role in dampening the inflammatory response in activated microglial cells (<ce:cross-ref id="crf0675" refid="fig0015">Fig. 3</ce:cross-ref>) <ce:cross-ref id="crf0680" refid="bib0330">[66]</ce:cross-ref>. Gas6/Axl signaling, through the PI3K/Akt pathway, protects ODs from tumor necrosis factor (TNFα)-induced apoptosis <ce:italic>in vitro</ce:italic>. In <ce:italic>in vivo</ce:italic> experimental autoimmune encephalomyelitis (EAE) models, elevated levels of TNFα correlate with lesions found, and transgenic mice expressing TNFα in the CNS show increased OD apoptosis and primary demyelination <ce:cross-ref id="crf0685" refid="bib0335">[67]</ce:cross-ref>. Studies from autoptic human MS lesions evidenced that sAxl is upregulated and negatively correlates with Gas6 expression. sAxl acts as a decoy receptor, sequestering Gas6, blocking its binding to full-length membrane-bound Axl and inhibiting Axl/Gas6 prosurvival activity on ODs <ce:cross-ref id="crf0690" refid="bib0215">[43]</ce:cross-ref>. To confirm this evidence, treatment with recombinant human Gas6 delivered directly into the CNS was demonstrated to protect axons from damage in EAE mice <ce:cross-ref id="crf0695" refid="bib0340">[68]</ce:cross-ref>. Axl/Gas6 signaling preferentially regulates phagocytosis and negative feedback pathways under inflammatory conditions. When decreased Axl activity is observed, ineffective engulfment of myelin debris is associated with increased CNS inflammation and a more exacerbated immune response, causing impaired remyelination in EAE models of MS <ce:cross-ref id="crf0700" refid="bib0345">[69]</ce:cross-ref>. Moreover, the specific contribution in remyelinating processes of Gas6/Axl signaling has been demonstrated in several studies based on single or double-knockout of <ce:italic>Axl</ce:italic> and its ligand. <ce:italic>Axl</ce:italic>
                     <ce:sup loc="post">–/–</ce:sup> mice show difficulties in clearing apoptotic ODs and myelin debris and a delayed recovery from demyelination induced by cuprizone, a copper chelator agent <ce:cross-ref id="crf0705" refid="bib0350">[70]</ce:cross-ref>. Gas6-knockout mice show a more severe cuprizone-induced demyelination compared with wild-type mice and an increased microglia activation responsible for greater OD loss and delayed remyelination <ce:cross-ref id="crf0710" refid="bib0355">[71]</ce:cross-ref>. In Gas6/Axl double-knockout mice, cuprizone administration is associated with an abnormal inflammatory response because of the reduced expression of SOCS1 and SOCS3. In these mice, the absence of both Gas6 and Axl and the inability of the latter to form heterodimers through its crosstalk with other RTKs significantly dampen the resolution of inflammation and the related remyelinating process cannot be compensated by other TAM receptors or their ligand protein S <ce:cross-ref id="crf0715" refid="bib0280">[56]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0120" view="all">Current MS pharmacological treatments focus on modulation of the immune responses but are ineffective in promoting axon remyelination processes and CNS repair <ce:cross-refs id="crfs0095" refid="bib0280 bib0360">[56,72]</ce:cross-refs>. To date, therapies aimed at remyelination have shown only modest results and have yet to be approved for use in the clinic <ce:cross-ref id="crf0720" refid="bib0360">[72]</ce:cross-ref>. Therefore, a potential novel strategy for preventing or ameliorating MS-associated demyelination is to inhibit the death of damaged ODs by targeting the Axl/Gas6 molecular system involved in myelin sheath repair. In particular, it would be desirable to develop novel molecules able to selectively target the Axl receptor, which is involved in dampening CNS inflammation, inducing its dimerization and activation. These molecules would represent new potential drugs for MS treatment, with anti-inflammatory, neuroprotective, and remyelination effects.</ce:para>
                  <ce:para id="par0125" view="all">Besides therapy, the Axl/Gas6 system could also be explored for diagnostic applications in MS. Concentrations of Gas6 into the cerebrospinal fluid (CSF) of patients with MS could represent a useful biomarker of disease progression, because Gas6 levels in CFS inversely correlate with relapse severity. More precisely, no variations in Gas6 concentration in the CSF are observed in the case of a severe relapse, whereas significant increases of Gas6 levels in CSF are observed during milder relapses. Therefore, Gas6 dosing in the CSF could be useful to predict the severity of an occurring MS relapse <ce:cross-ref id="crf0725" refid="bib0365">[73]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0130" view="all">Similarly to MS, an alteration of Gas6 levels in the CSF has also been observed in chronic inflammatory demyelinating polyneuropathy (CIDP) and in patients with Alzheimer’s disease <ce:cross-refs id="crfs0100" refid="bib0370 bib0375">[74,75]</ce:cross-refs>.</ce:para>
               </ce:section>
               <ce:section id="sec0025" view="all">
                  <ce:section-title id="sect0035">Role of Axl/Gas6 proteins in viral infection</ce:section-title>
                  <ce:para id="par0135" view="all">Over the past few decades, several studies have focused on the role of Axl/Gas6 in enveloped virus infection mechanisms. In particular, strong evidence has been reported from ZIKV <ce:cross-ref id="crf0730" refid="bib0060">[12]</ce:cross-ref>, EBV <ce:cross-ref id="crf0735" refid="bib0065">[13]</ce:cross-ref>, and Dengue virus <ce:cross-ref id="crf0740" refid="bib0380">[76]</ce:cross-ref> infections. Specifically, the Axl/Gas6 axis is involved in viral entry that occurs as consequence of the apoptotic mimicry process in which the PtdSer displayed on the virus envelope has an important role for the engulfment mechanism mediated by host cells <ce:cross-ref id="crf0745" refid="bib0385">[77]</ce:cross-ref>. Both Axl and Gas6 are required for virus infection. Axl works as an entry receptor and Gas6 acts as bridging molecule between the viral PtdSer and Axl receptor on host cells (<ce:cross-ref id="crf0750" refid="fig0020">Fig. 4</ce:cross-ref>
                     <ce:float-anchor refid="fig0020"/></ce:float-anchor>). Following the bridging step mediated by Gas6/PtdSer binding, the virus particle is internalized via clathrin-mediated endocytosis, establishing active viral infection in endosomes <ce:cross-refs id="crfs0105" refid="bib0060 bib0380 bib0390">[12,76,78]</ce:cross-refs>. Axl also has a role as an immune modulator of the virus inside the host cell. In fact, ZIKV activates Axl kinase activity to antagonize type I IFN signaling <ce:cross-ref id="crf0755" refid="bib0060">[12]</ce:cross-ref>. Available evidence suggests that ZIKV infection in mammals can also occur in an Axl-independent manner <ce:cross-refs id="crfs0110" refid="bib0395 bib0400">[79,80]</ce:cross-refs>. The importance of Axl tyrosine kinase activity in strengthening viral infection has also been highlighted in Dengue <ce:cross-ref id="crf0760" refid="bib0380">[76]</ce:cross-ref> and EBV infections. In the latter, Axl mutants analyses showed that phosphorylation of receptor tyrosine residues inside its C-terminal tail is necessary for efficient enhancement of the infection <ce:cross-ref id="crf0765" refid="bib0065">[13]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0140" view="all">In ZIKV infection, Axl also has a significant role in the enhancement of virus infection in a cell type-specific manner <ce:cross-refs id="crfs0115" refid="bib0060 bib0405 bib0410 bib0415">[12,81–83]</ce:cross-refs>. ZIKV infects human Sertoli cells (SCs), which show a high basal expression of Axl. SCs are present in the epithelium of seminiferous tubules, the site of spermatozoa development. Therefore, the testes are the only organs in adult humans where ZIKV can establish a persistent infection, thus presenting a risk for pregnant women of acquiring ZIKV from male partners <ce:cross-ref id="crf0770" refid="bib0420">[84]</ce:cross-ref>. Moreover, ZIKV can be transmitted from the pregnant mother to the fetus <ce:cross-refs id="crfs0120" refid="bib0405 bib0425">[81,85]</ce:cross-refs>. In this case, human ECs and Axl, which promotes ZIKV entry also at a postbinding step through its tyrosine kinase activity, have an important role <ce:cross-ref id="crf0775" refid="bib0415">[83]</ce:cross-ref>. After a mosquito bite, ZIKV reaches the bloodstream, where the virus directly infects human ECs. The release of viral particles by ECs facilitates the hematogenous spread of ZIKV, bypassing the barriers that normally act against viral infection. In this way, the virus can easily reach tissues that viruses typically cannot infect, such as the blood–testis barrier (BTB), the blood–brain barrier (BBB) and part of the placental–blood barrier (PBB) <ce:cross-refs id="crfs0125" refid="bib0415 bib0420">[83,84]</ce:cross-refs>. Richard <ce:italic>et al.</ce:italic> showed that Axl is able to implement ZIKV entry in ECs more efficiently than in Dengue virus. They speculated that ZIKV, but not Dengue virus, shows a capacity to bind Gas6 efficiently, using Axl to infect fetal ECs, crossing the PBB, and explaining why only ZIKV, and no other flaviviruses, can infect fetal tissues causing congenital malformation <ce:cross-ref id="crf0780" refid="bib0405">[81]</ce:cross-ref>. Axl is expressed in human microglia and astrocytes in the developing brain, where it mediates ZIKV infection at an early stage. In fact, infection of pregnant women is associated with fetal abnormalities, congenital microcephaly, and abortion.</ce:para>
                  <ce:para id="par0145" view="all">On the basis of its transmission mechanisms, ZIKV represents an emerging pathogen also responsible for adult neurological disorders <ce:cross-ref id="crf0785" refid="bib0430">[86]</ce:cross-ref>. To date, ZIKV has been detected in the human CNS, blood, saliva, semen and urine, suggesting that the virus has developed mechanisms to reach multiple tissues <ce:cross-ref id="crf0790" refid="bib0415">[83]</ce:cross-ref>. In ZIKV infection, the Axl receptor has also a pivotal role in dampening the innate antiviral response in the testis, glial cells, as well as in other cell types <ce:cross-refs id="crfs0130" refid="bib0060 bib0420">[12,84]</ce:cross-refs> because it can form a complex with the subunit 1 of the IFN-α/β receptor (IFNAR1). This complex is able to modify canonical IFNAR function <ce:cross-ref id="crf0795" refid="bib0435">[87]</ce:cross-ref> and, upon Gas6 ligand binding, produces the autophosphorylation of signal transducer and activator of transcription 1 (STAT1) homodimers that translocate into the nucleus and initiate the expression of SOCS1 and SOCS3. These, in turn, suppress type I IFN production, facilitating viral replication (<ce:cross-ref id="crf0800" refid="fig0020">Fig. 4</ce:cross-ref>). The inhibition of Axl kinase leads to decreased levels of SOCS1 and SOCS3, increased expression of IFN-stimulated genes and reduced ZIKV replication, even if it does not affect ZIKV entry <ce:cross-refs id="crfs0135" refid="bib0060 bib0420">[12,84]</ce:cross-refs>. Currently, there are no therapies or specific treatments for clearing ZIKV infection from testis <ce:cross-ref id="crf0805" refid="bib0420">[84]</ce:cross-ref> and ZIKV infection during pregnancy is often correlated with fetal death or injury to the fetal CNS <ce:cross-ref id="crf0810" refid="bib0430">[86]</ce:cross-ref>. Moreover, ZIKV-related Guillain–Barré syndrome leads in affected adults to the onset of neurological features that resemble those associated with autoimmune neuropathies <ce:cross-ref id="crf0815" refid="bib0440">[88]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0030" view="all">
                  <ce:section-title id="sect0040">Axl/Gas6 targeting in biomedicine</ce:section-title>
                  <ce:para id="par0150" view="all">Axl and Gas6 are attractive target candidates for the development of novel molecules for therapeutic or diagnostic applications. In cancer, Axl/Gas6-blocking molecules could be a potent weapon to counteract tumor growth and metastatic progression and, notably, to recover drug sensitivity in patients with advanced-stage cancers. Given the potential role of by Axl and Gas6 as cancer biomarkers, molecules targeting Axl or Gas6 might also be useful as diagnostic and prognostic tools in cancer imaging. Gas6 and its receptors also represent a potential therapeutic target in the treatment of pathological conditions characterized by fibrosis, which is the excessive deposition of extracellular matrix following a tissue injury. Gas6 and TAM receptors have been correlated with several types of human fibrosis, such as lung, liver, and kidney fibrosis <ce:cross-refs id="crfs0140" refid="bib0070 bib0445 bib0450 bib0455 bib0460">[14,89–92]</ce:cross-refs>. Molecules negatively regulating Axl/Gas6 signaling also show potential application in combatting viral infections, given that the Axl/Gas6 system is involved in the viral entry mechanism of emerging pathogens, such as ZIKV. Gas6 agonists, able to activate Axl signaling, could find potential application in the treatment of MS, in which the Axl/Gas6 system is downregulated. Over the past few years, efforts to find modulators of Axl/Gas6 activity led to the development of a collection of molecules targeting Axl or Gas6, some of which are in clinical trials. Different molecular approaches have been reported to target the Axl/Gas6 system, including small organic molecules, aptamers, recombinant proteins, antibodies, and cell-based systems (<ce:cross-ref id="crf0820" refid="fig0025">Fig. 5</ce:cross-ref>
                     <ce:float-anchor refid="fig0025"/></ce:float-anchor> and <ce:cross-ref id="crf0825" refid="tbl0010">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl0010"/></ce:float-anchor>). Although most show application in cancer therapy, evaluation for use in other pathologies is likely, especially in the treatment of autoimmune diseases and enveloped virus infections, or in molecular imaging applications.</ce:para>
               </ce:section>
               <ce:section id="sec0035" view="all">
                  <ce:section-title id="sect0045">Axl/Gas6 small-molecule inhibitors</ce:section-title>
                  <ce:section id="sec0040" view="all">
                     <ce:section-title id="sect0050">Tyrosine kinase inhibitors</ce:section-title>
                     <ce:para id="par0155" view="all">Several small organic molecules (<ce:cross-ref id="crf0830" refid="fig0030">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig0030"/></ce:float-anchor>) able to target and inhibit the TK domain of Axl receptor have been developed and reported as anticancer drugs <ce:cross-ref id="crf0835" refid="bib0075">[15]</ce:cross-ref>. Most Axl TK inhibitors (TKIs) do not selectively act on the Axl receptor but are dual or multitarget drugs. A few specific or highly selective inhibitors acting on Axl as a single target have been described but none have entered the clinic, although many trials are ongoing (<ce:cross-ref id="crf0840" refid="tbl0010">Table 1</ce:cross-ref>). TKIs are mainly ATP-competitive molecules containing an adenine-mimicking heterocyclic moiety that binds to the hinge region of the ATP site in the kinase domain. TKIs are classified as type I, which interact with the kinase domain in the active conformation, or type I, which bind instead to the inactive conformation of the kinase domain. Bemcentinib (BGB324 or R428) <ce:cross-ref id="crf0845" refid="bib0465">[93]</ce:cross-ref> is the first-in-class and best-characterized specific and highly selective Axl TKI that is expected to be approved for cancer therapy. Currently, five clinical trials are under analysis and another has been completed. Bemcentinib was developed by high-throughput screening followed by structure–activity relationship modifications aimed at increasing potency and selectivity. An inhibitory activity of bemcentinib against other TKs has also been observed <ce:cross-refs id="crfs0145" refid="bib0470 bib0475">[94,95]</ce:cross-refs>. Bemcentinib inhibits Axl phosphorylation at a low nano-molar concentration (IC<ce:inf loc="post">50</ce:inf> 14<ce:hsp sp="0.25"/></ce:hsp>nM), blocking Axl signaling and showing potent anticancer activity in several types of aggressive tumor, such as triple-negative breast cancer (TNBC), CML, acute myeloid leukemia (AML), Ewing sarcoma, and esophageal squamous cell carcinoma <ce:cross-refs id="crfs0150" refid="bib0465 bib0480 bib0485 bib0490 bib0495">[93,96–99]</ce:cross-refs>. In tumor models, bemcentinib was also demonstrated to enhance the efficacy of chemotherapy and radiation and to recover drug sensitivity <ce:cross-refs id="crfs0155" refid="bib0480 bib0500">[96,100]</ce:cross-refs>.</ce:para>
                     <ce:para id="par0160" view="all">Although most experimental biological data regarding Axl/Gas6 inhibitors relate to their efficacy as anticancer drugs, Axl/Gas6 targeting with a small inhibitor has also been explored in other pathologies. For instance, Axl inhibition by bemcentinib was also evaluated in the treatment of: idiopathic pulmonary fibrosis (IPF), where it significantly inhibited the synthetic, migratory, and proliferative properties of IPF fibroblasts <ce:cross-ref id="crf0850" refid="bib0445">[89]</ce:cross-ref>; in nonalcoholic steatohepatitis <ce:cross-ref id="crf0855" refid="bib0505">[101]</ce:cross-ref>; liver fibrosis <ce:cross-ref id="crf0860" refid="bib0450">[90]</ce:cross-ref>; kidney fibrosis <ce:cross-ref id="crf0865" refid="bib0460">[92]</ce:cross-ref>; and lupus nephritis <ce:cross-ref id="crf0870" refid="bib0510">[102]</ce:cross-ref>. Bemcentinib was also demonstrated to counteract Gas6-induced pre-eclampsia progression in pregnant rats <ce:cross-ref id="crf0875" refid="bib0515">[103]</ce:cross-ref>. Axl/Gas6 blocking with small targeting molecules has also been suggested as a therapeutic approach to tackle ZIKV infection <ce:cross-refs id="crfs0160" refid="bib0060 bib0420">[12,84]</ce:cross-refs>. In particular, bemcentinib was able to attenuate ZIKV infection in cell cultures of SCs, human testicular organoids, and human microglial cells <ce:cross-refs id="crfs0165" refid="bib0060 bib0420">[12,84]</ce:cross-refs>. Other Axl-specific TKI inhibitors include an 18-atom macrocyclic inhibitor assembled through click-chemistry <ce:cross-ref id="crf0880" refid="bib0520">[104]</ce:cross-ref>, eSM134 <ce:cross-ref id="crf0885" refid="bib0470">[94]</ce:cross-ref>, and DP-3975 <ce:cross-ref id="crf0890" refid="bib0525">[105]</ce:cross-ref>. However, these show higher IC<ce:inf loc="post">50</ce:inf> values <ce:italic>in vitro</ce:italic> compared with bemcentinib <ce:cross-refs id="crfs0170" refid="bib0075 bib0470">[15,94]</ce:cross-refs>. Axl kinase inhibitors that are more potent than bemcentinib were also reported, such as DS-1205b, 9im, and 2D08 with an <ce:italic>in vitro</ce:italic> IC<ce:inf loc="post">50</ce:inf> of 1.3<ce:hsp sp="0.25"/></ce:hsp>nM, 4<ce:hsp sp="0.25"/></ce:hsp>nM, and 0.49<ce:hsp sp="0.25"/></ce:hsp>nM, respectively <ce:cross-refs id="crfs0175" refid="bib0475 bib0530 bib0535">[95,106,107]</ce:cross-refs>. However, these molecules are still in the preclinical stage of development. Nevertheless, DS-1205c, an inhibitor molecule structurally related to DS-1205b, reached clinical evaluation for the treatment of nonsmall cell lung cancer (NSCLC) in combination with osimertinib or gefitinib (ClinicalTrials.gov: NCT03255083 and NCT03599518).</ce:para>
                     <ce:para id="par0165" view="all">Several multitarget TKIs, exerting their effect by inhibiting Axl among other TK receptors, have been approved and entered the pharmaceutical market as anticancer therapeutics, such as bosutinib <ce:cross-ref id="crf0895" refid="bib0540">[108]</ce:cross-ref>, cabozantinib <ce:cross-ref id="crf0900" refid="bib0545">[109]</ce:cross-ref>, crizotinib <ce:cross-ref id="crf0905" refid="bib0550">[110]</ce:cross-ref>, gilteritinib <ce:cross-ref id="crf0910" refid="bib0555">[111]</ce:cross-ref>, and sunitinib <ce:cross-ref id="crf0915" refid="bib0560">[112]</ce:cross-ref>. Such molecules have been designed against other target receptors, such as Src and Abl kinases, Met, Mer, VEGFR2, PDGFR, and Flt3, but, because of the high similarity between their TK domains, they also showed inhibitory activity against Axl. Interestingly, the TKI BMS-777607, originally discovered as a Met inhibitor, showed a threefold greater potency against Axl (IC<ce:inf loc="post">50</ce:inf> 1.1<ce:hsp sp="0.25"/></ce:hsp>nM) compared with Met <ce:cross-ref id="crf0920" refid="bib0565">[113]</ce:cross-ref>. Biological characterization of BMS-777607 showed its Axl-mediated antitumor activity in glioblastoma multiforme <ce:cross-ref id="crf0925" refid="bib0570">[114]</ce:cross-ref>. It was demonstrated to block Axl kinase function, resulting in the escape of the receptor from internalization and ubiquitin-related degradation mechanism, leading to the accumulation of Axl on the cell surface <ce:cross-ref id="crf0930" refid="bib0575">[115]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0045" view="all">
                     <ce:section-title id="sect0055">Nontyrosine kinase inhibitors</ce:section-title>
                     <ce:para id="par0170" view="all">A few small organic molecules working as Axl/Gas6 inhibitors that target Gas6 or the extracellular Axl ectodomain (Axl-ECD) have also been described.</ce:para>
                     <ce:para id="par0175" view="all">Warfarin, a vitamin K antagonist clinically used as an antithrombotic drug, blocks Gas6 at a lower concentration than that required to exert its anticoagulation effects <ce:cross-refs id="crfs0180" refid="bib0580 bib0585">[116,117]</ce:cross-refs>. Warfarin acts indirectly, by inhibiting the γ-carboxylation of the Gas6 GLA domain, preventing Gas6 binding to PtdSer and, thus, rendering Gas6 unable to activate Axl <ce:cross-ref id="crf0935" refid="bib0590">[118]</ce:cross-ref>. Warfarin has also shown anticancer effects <ce:cross-ref id="crf0940" refid="bib0595">[119]</ce:cross-ref>. Gas6/Axl inhibition with warfarin was also useful in preventing the progression of diabetic nephropathy in diabetic rats <ce:cross-ref id="crf0945" refid="bib0600">[120]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0180" view="all">The small inhibitors RU-301 and RU-302 block Axl activation by targeting a region at the interface between the Axl-Ig1 domain and the Gas6-LG1 domain <ce:cross-ref id="crf0950" refid="bib0605">[121]</ce:cross-ref>. RU-301 and RU-302 were developed by rational drug design, demonstrated inhibitory activity against Axl in cell-based reporter assays, and were able to inhibit tumor growth <ce:italic>in vivo</ce:italic> in a lung cancer xenograft model.</ce:para>
                     <ce:para id="par0185" view="all">Various natural compounds have also shown inhibitory activity against Axl receptor, although the molecular mechanisms involved have not always clarified <ce:cross-refs id="crfs0185" refid="bib0075 bib0255">[15,51]</ce:cross-refs>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0050" view="all">
                     <ce:section-title id="sect0060">Aptamers</ce:section-title>
                     <ce:para id="par0190" view="all">By combining the SELEX screening technique and rational design approaches, Cerchia <ce:italic>et al.</ce:italic> identified a 34-<ce:italic>mer</ce:italic> RNA aptamer, GL21.T, that targets the extracellular region of Axl with high affinity (K<ce:inf loc="post">d</ce:inf> 12<ce:hsp sp="0.25"/></ce:hsp>nM) and inhibits Axl phosphorylation and intracellular signaling mediated by ERK and AKT. <ce:italic>In vivo</ce:italic> experiments on lung cancer xenograft models demonstrated that GL21.T efficiently inhibited tumor growth <ce:cross-ref id="crf0955" refid="bib0610">[122]</ce:cross-ref>. The GL21.T aptamer was also exploited as homing unit to selectively deliver a therapeutic miRNA to Axl-positive cancer cells <ce:cross-ref id="crf0960" refid="bib0615">[123]</ce:cross-ref>. The GL21.T nucleotide sequence was also synthesized in the corresponding DNA aptamer, introducing 2′-fluoro modifications on the pyrimidines as well as monothiophosphate modifications on selected nucleotides. The modified DNA aptamer was resistant to hydrolysis in serum and was able to inhibit Axl signaling <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>. In addition, the DNA aptamer potentiated paclitaxel-based chemotherapy efficacy in ovarian cancer models <ce:cross-ref id="crf0965" refid="bib0620">[124]</ce:cross-ref>.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0055" view="all">
                  <ce:section-title id="sect0065">Protein-based molecules</ce:section-title>
                  <ce:para id="par0195" view="all">The use of protein-based therapeutics in biomedicine is of great utility respect to the use of conventional small molecule-based pharmaceuticals, mainly in terms of the affinity and specificity for the target. These features translate into a better toxicity profile, because protein-based therapeutics are usually well tolerated and less likely to cause adverse effects. Several protein-based molecules targeting Axl and Gas6 have been reported and some are currently in clinical trials. Most are monoclonal antibodies (mAb) blocking Axl/Gas6 signaling and showing antitumor activity. A recombinant decoy Axl receptor was also reported as an inhibitor of Axl signaling. Recombinant human Gas6 (or agonists thereof) was instead proposed to restore impaired Axl/Gas6 signaling in the treatment of autoimmune pathologies, such as MS. Peptides targeting Axl or Gas6 have yet to be reported. However, peptides represent an emerging class of pharmaceutical compounds featuring numerous advantages respect to conventional drugs, such as molecular weight <ce:cross-ref id="crf0970" refid="bib0625">[125]</ce:cross-ref>. Thus, the identification of peptide molecules targeting the Axl/Gas6 system might have a relevant clinical impact. In this context, the synthetic procedure for the preparation of the Axl-Ig2 domain in its D-enantiomeric form (D-Axl-2) was recently reported <ce:cross-ref id="crf0975" refid="bib0630">[126]</ce:cross-ref>. D-Axl-2 can be used for the selection of metabolically stable peptide binders of Axl receptor through the mirror-image phage display library screening approach <ce:cross-ref id="crf0980" refid="bib0635">[127]</ce:cross-ref>.</ce:para>
                  <ce:section id="sec0060" view="all">
                     <ce:section-title id="sect0070">Axl-targeting antibodies</ce:section-title>
                     <ce:para id="par0200" view="all">Several antibodies targeting and blocking Axl receptor have been developed using both library screening and hybridoma technologies. Anti-Axl antibodies find medical applications in cancer therapy and imaging. YW327.6S2, a mAb targeting both the human and murine Axl receptor with high affinity (K<ce:inf loc="post">d</ce:inf> of 1<ce:hsp sp="0.25"/></ce:hsp>nM and 545<ce:hsp sp="0.25"/></ce:hsp>pM, respectively), was selected from a phage-display antibodies library. It is able to block Axl signaling by competing with Gas6 binding. The antitumor efficacy of YW327.6S2 was assessed in A549 NSCLC and MDA-MB-231 TNBC xenograft models. In both models, YW327.6S2 downregulated Axl expression, reduced tumor growth, and enhanced the therapeutic effect of an anti-VEGF antibody. In NSCLC models, YW327.6S2 improved the therapeutic effect of the EGFR small-molecule inhibitor erlotinib and of the standard chemotherapy used for the treatment of NSCLC. In MDA-MB-231 TNBC xenograft models, YW327.6S2 reduced tumor vascular density and metastasis and inhibited the secretion of inflammatory cytokines and chemokines from tumor-associated macrophages <ce:cross-ref id="crf0985" refid="bib0640">[128]</ce:cross-ref>. DAXL-88 is another anti-Axl mAb selected by screening of a phage display library able to bind both human and murine Axl that has shown <ce:italic>in vitro</ce:italic> inhibitory effects against tumor cell migration and invasion <ce:cross-ref id="crf0990" refid="bib0645">[129]</ce:cross-ref>. A set of three mAbs (3G9, 8B5, and 12A11), generated by immunizing mice with the recombinant human Axl-ECD (rhAxl-ECD), were selected for their ability to downregulate Axl expression. Their antitumor efficacy was tested in NSCLC xenografts. Although only two of them, 3G9 and 8B5, were able to block Gas6 binding to Axl receptor, all the three mAbs reduced tumor growth. The binding epitope of each mAb to Axl was mapped and was shown to be located within the Ig-1 domain in the case of 3G9 and 8B5, consistent with their ability to block ligand binding to the receptor, whereas the epitope for 12A11 was mapped to the FNIII-1 domain <ce:cross-ref id="crf0995" refid="bib0650">[130]</ce:cross-ref>. Another anti-Axl antibody targeting the FNIII-1 domain of the receptor, MAb173, obtained by mouse immunization with Axl-ECD, showed <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> activity against Kaposi sarcoma <ce:cross-ref id="crf1000" refid="bib0655">[131]</ce:cross-ref>. Two other Axl-blocking mAbs (D9 and E8) were generated through the hybridoma technology, by mouse immunization with rhAxl-ECD. D9 and E8 were demonstrated to inhibit Axl signaling without interfering with Gas6 ligand binding but instead inducing reduced Axl expression by receptor internalization <ce:cross-ref id="crf1005" refid="bib0660">[132]</ce:cross-ref>. The antitumor efficacy of D9 and E8 was evaluated using <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> models of pancreatic cancer, demonstrating an inhibitory effect on the proliferation and migration of pancreatic cancer cells and a significantly reduced growth of both subcutaneous and orthotopic pancreatic tumor xenografts. The antitumor activity of the D9 mAbs was also evaluated in TNBC cell xenograft and patient-derived xenograft (PDX) models <ce:cross-ref id="crf1010" refid="bib0665">[133]</ce:cross-ref>, inhibiting both tumor growth and bone metastasis formation only in Axl-positive xenografts, highlighting the key role of Axl in cancer growth and invasion. Recently an antibody–drug conjugate (ADC) targeting the Axl receptor was reported that showed strong antitumor activity against a series of solid tumors, such NSCLC, cervical cancer, pancreatic cancer, and melanoma <ce:cross-refs id="crfs0190" refid="bib0670 bib0675">[134,135]</ce:cross-refs>. The anti-Axl ADC AXL-107-MMAE (enapotamab vedotin), was generated as a prodrug by conjugating the mAb (AXL-107) with the microtubule-disrupting agent monomethyl auristatin E (MMAE) through an intracellular cathepsin-cleavable valine-citrulline linker. AXL-107 did not interfere with Gas6 binding and unconjugated AXL-107 did not affect tumor cell viability, demonstrating that cytotoxicity was MMAE related. Enapotamab vedotin is currently under clinical-stage evaluation for the treatment of ovarian cancer, cervical cancer, endometrial cancer, NSCLC, thyroid cancer, melanoma, and sarcoma (ClinicalTrials.gov: NCT02988817). A conditionally active biologic anti-AXL-ADC, BA3011, in which MMAE is conjugated to an anti-Axl humanized mAb able to specifically bind Axl under conditions found within the tumor microenvironment, is also under clinical evaluation <ce:cross-ref id="crf1015" refid="bib0680">[136]</ce:cross-ref> (ClinicalTrials.gov: NCT03425279).</ce:para>
                     <ce:para id="par0205" view="all">Pioneering applications of Axl-targeting mAbs in bioimaging were also reported, suggesting that cancer imaging by Axl-targeting could aid tumor diagnosis, prognosis, and monitoring. Using <ce:italic>in vivo</ce:italic> models of TNBC, a DOTA-conjugated anti-Axl antibody labeled with <ce:sup loc="post">64</ce:sup>Cu was used to quantify by micro-PET/CT the reduction in Axl expression in response to 17-allylamino-17-demethoxygeldanamycin <ce:cross-ref id="crf1020" refid="bib0685">[137]</ce:cross-ref>, a potent inhibitor of heat-shock protein 90 that is under clinical evaluation and able to downregulate Axl expression <ce:cross-ref id="crf1025" refid="bib0690">[138]</ce:cross-ref>. A <ce:sup loc="post">125</ce:sup>I-radiolabeled anti-Axl mAb was investigated to detect Axl expression in pancreatic and prostate tumor xenografts, demonstrating specific and persistent accumulation in tumors expressing high levels of Axl <ce:cross-ref id="crf1030" refid="bib0695">[139]</ce:cross-ref>. A molecular probe for near-infrared fluorescence imaging of Axl expression in lung cancer xenografts was reported by Li <ce:italic>et al.</ce:italic> and prepared by conjugating a Cy5.5 fluorophore to the humanized anti-Axl MAb173 Ab (h173) <ce:cross-ref id="crf1035" refid="bib0700">[140]</ce:cross-ref>. The same antibody was also used to develop an Axl-targeting probe for cancer imaging by PET <ce:cross-ref id="crf1040" refid="bib0705">[141]</ce:cross-ref>. In this case, h173 was conjugated to the DOTA chelator and radiolabeled with <ce:sup loc="post">64</ce:sup>Cu.</ce:para>
                  </ce:section>
                  <ce:section id="sec0065" view="all">
                     <ce:section-title id="sect0075">Gas6-neutralizing proteins</ce:section-title>
                     <ce:para id="par0210" view="all">Another way to block Axl signaling refers to the sequestering of its ligand using Gas6-neutralizing proteins, (i.e., mAbs and decoy receptors). The utility of Gas6-targeting mAbs as Gas6-neutralizing agents in anticancer therapy was explored by Moody <ce:italic>et al.</ce:italic>, who reported the generation by XenoMouse® technology of a fully human GMAB1 mAb able to fully sequester Gas6. GMAB1 anticancer efficacy was tested against human pancreatic adenocarcinoma xenografts and was able to inhibit tumor growth <ce:cross-ref id="crf1045" refid="bib0710">[142]</ce:cross-ref>. Previously, a Gas6-neutralizing mAb, named CNTO300, was exploited to better map the interaction surface between Axl and Gas6 <ce:cross-ref id="crf1050" refid="bib0715">[143]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0215" view="all">An engineered Axl decoy receptor, MYD1, able to bind Gas6 with significantly higher affinity than the natural receptor, was also described <ce:cross-ref id="crf1055" refid="bib0720">[144]</ce:cross-ref>. The decoy receptor was developed applying rational drug design and a combinatorial approach to improve the binding properties of the Ig1 domain of Axl, the receptor region that includes the major binding site for Gas6. The engineered Ig1 was then cloned back into <ce:italic>Axl</ce:italic> and fused to the Fc domain of a human IgG1, leading to a decoy receptor showing further improved binding properties (K<ce:inf loc="post">d</ce:inf> of 420<ce:hsp sp="0.25"/></ce:hsp>fM). The decoy receptor was demonstrated to sequester Gas6 <ce:italic>in vivo</ce:italic> and potently inhibit metastasis and tumor progression in models of advanced ovarian or breast cancer. Interestingly, the Axl decoy receptor was able to prevent ZIKV infection in human microglial cells by sequestering Gas6 and blocking virus binding to Axl <ce:cross-ref id="crf1060" refid="bib0060">[12]</ce:cross-ref>. A second-generation Fc-fused Axl decoy receptor (MYD1-72), showing an even higher affinity against Gas6 (K<ce:inf loc="post">d</ce:inf> of 93<ce:hsp sp="0.25"/></ce:hsp>fM) and a superior anti-tumor efficacy, was successively developed <ce:cross-ref id="crf1065" refid="bib0725">[145]</ce:cross-ref>. The Axl decoy receptor is in clinical studies with the name AVB-S6-500. A series of Axl-ECD-Fc decoy receptor variants able to block Axl/Gas6 signaling was also developed by computational analysis <ce:cross-ref id="crf1070" refid="bib0730">[146]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0070" view="all">
                     <ce:section-title id="sect0080">rGas6</ce:section-title>
                     <ce:para id="par0220" view="all">Given the role of Gas6/Axl signaling as negative regulator of the immune response, such molecular systems have gained interest as a biological target for the treatment of autoimmune diseases, especially MS. The administration of recombinant Gas6 (rGas6) by intracerebral route has been demonstrated by <ce:italic>in vivo</ce:italic> experiments in mouse models of MS to exert a protective and regenerative effect on CNS <ce:cross-refs id="crfs0195" refid="bib0340 bib0735">[68,147]</ce:cross-refs>. Besides MS, rGas6 has also been demonstrated to exert a therapeutic effect in other autoimmune pathologies, such as autoimmune thyroiditis <ce:cross-ref id="crf1075" refid="bib0740">[148]</ce:cross-ref>. An adenoviral vector overexpressing Gas6 was injected into a mouse model of arthritis, ameliorating the pathology symptoms and, thus, suggesting a novel therapeutic strategy to treat RA <ce:cross-ref id="crf1080" refid="bib0745">[149]</ce:cross-ref>. rGas6 administration was also showed to attenuate brain injury in an intracerebral hemorrhage mouse model <ce:cross-ref id="crf1085" refid="bib0750">[150]</ce:cross-ref>, to exert positive effect in a sepsis mouse model <ce:cross-ref id="crf1090" refid="bib0755">[151]</ce:cross-ref>, and in an ischemia-reperfusion-induced acute lung injury rat model <ce:cross-ref id="crf1095" refid="bib0760">[152]</ce:cross-ref>.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0075" view="all">
                  <ce:section-title id="sect0085">Cell-based therapy</ce:section-title>
                  <ce:para id="par0225" view="all">Recently, the Axl receptor was explored as target for the development of a novel chimeric antigen receptor-modulated T lymphocyte (CAR-T) therapy <ce:cross-refs id="crfs0200" refid="bib0765 bib0770">[153,154]</ce:cross-refs>. T cells were genetically engineered to express a membrane receptor exposing an anti-Axl scFv, becoming able to target Axl-positive cancer cells. The utility of this innovative therapeutic approach was explored in the treatment of TNBC, an aggressive form of solid tumor that currently lacks a efficacious therapy <ce:cross-ref id="crf1100" refid="bib0770">[154]</ce:cross-ref>. Axl-CAR-T cells revealed an antigen-specific cytotoxicity and ability to release cytokines in a TNBC cell line as well as a significant antitumor effect in a TNBC xenograft model. The antitumor efficacy of the Axl-targeting CAR-T cells on TNBC models was further improved by co-expressing on the engineered T lymphocytes a constitutively activated IL-7 receptor (C7R) <ce:cross-ref id="crf1105" refid="bib0775">[155]</ce:cross-ref>. Notably, the anticancer effect of autologous T cells engineered to express a CAR targeting Axl and reinfused in patients with relapsed and refractory stage IV metastatic renal cell carcinoma (RCC) is under evaluation in a clinical trial (ClinicalTrials.gov Identifier: NCT03393936). A cell therapy system using T-lymphocytes expressing anti-Axl synNotch receptor was also reported <ce:cross-ref id="crf1110" refid="bib0765">[153]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0080" view="all">
                  <ce:section-title id="sect0090">Concluding remarks</ce:section-title>
                  <ce:para id="par0230" view="all">The Axl/Gas6 molecular system has a major role in several pathological conditions that urgently need more effective therapeutic and diagnostic tools, such as cancer, autoimmune diseases and, notably, viral infections. Although there is more to be learnt about the biology of the system, especially Axl receptor activation and signaling, experimental evidence is providing increased understanding of the role of Axl/Gas6 in several diseases. A range of molecules targeting Axl and Gas6 have been developed. Although none have yet been introduced into the clinic, they are currently under study in clinical trials and some are expected to be approved, especially as cancer therapies, significantly expanding the armamentarium of drugs available to fight several high social-impact diseases.</ce:para>
                  <ce:para id="par0235" view="all">Nevertheless, the potential of this system from a drug discovery perspective is far from being fully realized. In fact, pathologies other than cancer have not yet been completely explored with Axl/Gas6 modulators for pharmacological applications. Moreover, increased effort is needed to find novel peptides and/or peptidomimetics able to modulate the Axl/Gas6 axis. Axl/Gas6 research will also benefit from the development of imaging probes targeting the Axl receptor, which could be useful to better understand the biology of Axl in pathological contexts and for diagnostic applications, especially in cancer. From this perspective, peptide-based molecules targeting Axl could represent significant advances because of their well-known advantages in molecular imaging.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0005" view="all">
               <ce:section-title id="sect0095">Acknowledgment</ce:section-title>
               <ce:para id="par0240" view="all">L.D.R. is supported by a <ce:grant-sponsor id="gs0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Fondazione Umberto Veronesi ‘Post-doctoral Fellowships 2020’</ce:grant-sponsor>.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl0005" view="all">
               <ce:section-title id="sect0100">References</ce:section-title>
               <ce:bibliography-sec id="bibs0005" view="all">
                  <ce:bib-reference id="bib0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lemke</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biology of the TAM receptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cold Spring Harb. Perspect. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>a009076</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lemke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.V.</ce:given-name>
                                 <ce:surname>Rothlin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Immunobiology of the TAM receptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>327</sb:first-page>
                              <sb:last-page>336</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>769</sb:first-page>
                              <sb:last-page>785</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Byers</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>279</sb:first-page>
                              <sb:last-page>290</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.F.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>852</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.D.</ce:given-name>
                                 <ce:surname>Dunne</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>164</sb:first-page>
                              <sb:last-page>175</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>24</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>36956</sb:first-page>
                              <sb:last-page>36970</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Diagn. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>425</sb:first-page>
                              <sb:last-page>429</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gjerdrum</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1124</sb:first-page>
                              <sb:last-page>1129</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wium</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The dual role of TAM receptors in autoimmune diseases and cancer: an overview</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cells</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:article-number>166</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bellan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Gas6/TAM system and multiple sclerosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:article-number>1807</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meertens</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>324</sb:first-page>
                              <sb:last-page>333</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shimojima</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The mechanism of Axl-mediated Ebola virus infection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Infect. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>196</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl. 2</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S259</sb:first-page>
                              <sb:last-page>263</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bellan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6/TAM system: a key modulator of the interplay between inflammation and fibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>5070</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>153</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transforming genes in chronic myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>85</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>1988</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1952</sb:first-page>
                              <sb:last-page>1956</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>O’Bryan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>1991</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5016</sb:first-page>
                              <sb:last-page>5031</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Chun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-inflammatory role of TAM family of receptor tyrosine kinases via modulating macrophage functioN</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cells</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>7</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yamagata</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synaptic adhesion molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>621</sb:first-page>
                              <sb:last-page>632</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sasaki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis for Gas6-Axl signalling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>80</sb:first-page>
                              <sb:last-page>87</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.N.</ce:given-name>
                                 <ce:surname>Stitt</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>661</sb:first-page>
                              <sb:last-page>670</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sadahiro</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3002</sb:first-page>
                              <sb:last-page>3013</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.D.</ce:given-name>
                                 <ce:surname>Lew</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Differential TAM receptor-ligand–phospholipid interactions delimit differential TAM bioactivities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Elife</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:article-number>e03385</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Healy</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Physiol. Lung Cell. Mol. Physiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>L1273</sb:first-page>
                              <sb:last-page>L1281</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Prieto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and Mer in the developing rat central nervous system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comp. Neurol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>425</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>295</sb:first-page>
                              <sb:last-page>314</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakano</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>323</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>387</sb:first-page>
                              <sb:last-page>392</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Laurance</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth arrest-specific gene 6 (gas6) and vascular hemostasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Nutr.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>196</sb:first-page>
                              <sb:last-page>203</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lacroix</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Dignat-George</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Thromb. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>129</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl. 2</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S27</sb:first-page>
                              <sb:last-page>S29</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schoumacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Burbridge</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Braunger</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>22</sb:issue-nr>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2619</sb:first-page>
                              <sb:last-page>2631</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Linger</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>35</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Tondo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptor pathways at the crossroads of neuroinflammation and neurodegeneration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dis Markers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2019</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2387614</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.V.</ce:given-name>
                                 <ce:surname>Rothlin</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptors are pleiotropic inhibitors of the innate immune response</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1124</sb:first-page>
                              <sb:last-page>1136</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ni</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6 attenuates sepsis-induced tight junction injury and vascular endothelial hyperpermeability via the Axl/NF-kappaB signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>662</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zagorska</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Diversification of TAM receptor tyrosine kinase function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>920</sb:first-page>
                              <sb:last-page>928</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>van der Meer</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>123</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>16</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2460</sb:first-page>
                              <sb:last-page>2469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Grabiec</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>855</sb:first-page>
                              <sb:last-page>860</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Grabiec</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Allergy Clin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>140</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>1144–1146 e1144</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Orme</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>169</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>58</sb:first-page>
                              <sb:last-page>68</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular pathways: receptor ectodomain shedding in treatment, resistance, and monitoring of cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>623</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ekman</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Thromb. Haemost.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>838</sb:first-page>
                              <sb:last-page>844</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Staufer</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e3135</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Weinger</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Up-regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates with Gas6 in established multiple sclerosis lesions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>175</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>283</sb:first-page>
                              <sb:last-page>293</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0220">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.B.</ce:given-name>
                                 <ce:surname>Rankin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Giaccia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The receptor tyrosine kinase AXL in cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers (Basel)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:article-number>103</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.Y.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>29</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4044</sb:first-page>
                              <sb:last-page>4055</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Linger</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1073</sb:first-page>
                              <sb:last-page>1090</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Holland</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multiple roles for the receptor tyrosine kinase axl in tumor formation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9294</sb:first-page>
                              <sb:last-page>9303</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gallicchio</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1970</sb:first-page>
                              <sb:last-page>1976</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0245">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref0245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>McShane</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptors in cardiovascular disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cardiovasc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1286</sb:first-page>
                              <sb:last-page>1295</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0250">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref0250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nalwoga</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strong expression of hypoxia-inducible factor-1alpha (HIF-1alpha) is associated with Axl expression and features of aggressive tumors in African breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e0146823</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0255">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref0255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Corno</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of the receptor tyrosine kinase Axl and its targeting in cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>15</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1496</sb:first-page>
                              <sb:last-page>1512</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0260">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref0260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Goyette</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The receptor tyrosine kinase AXL is required at multiple steps of the metastatic cascade during HER2-positive breast cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1476</sb:first-page>
                              <sb:last-page>1490</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0265">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref0265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Taniguchi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>259</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0270">
                     <ce:label>54</ce:label>
                     <sb:reference id="sbref0270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Budagian</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>24</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4260</sb:first-page>
                              <sb:last-page>4270</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0275">
                     <ce:label>55</ce:label>
                     <sb:reference id="sbref0275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mudduluru</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>25</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2888</sb:first-page>
                              <sb:last-page>2899</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0280">
                     <ce:label>56</ce:label>
                     <sb:reference id="sbref0280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Glia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2051</sb:first-page>
                              <sb:last-page>2069</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0285">
                     <ce:label>57</ce:label>
                     <sb:reference id="sbref0285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.Q.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptors in apoptotic cell clearance, autoimmunity, and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Autoimmunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>294</sb:first-page>
                              <sb:last-page>297</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0290">
                     <ce:label>58</ce:label>
                     <sb:reference id="sbref0290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Gheita</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçet’s disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1279</sb:first-page>
                              <sb:last-page>1286</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0295">
                     <ce:label>59</ce:label>
                     <sb:reference id="sbref0295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.H.</ce:given-name>
                                 <ce:surname>Bassyouni</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Diminished soluble levels of growth arrest specific protein 6 and tyrosine kinase receptor Axl in patients with rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Rheum Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>53</sb:first-page>
                              <sb:last-page>59</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0300">
                     <ce:label>60</ce:label>
                     <sb:reference id="sbref0300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ekman</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Critical Care</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:article-number>R158</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0305">
                     <ce:label>61</ce:label>
                     <sb:reference id="sbref0305">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Salmi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6/TAM axis in sepsis: time to consider its potential role as a therapeutic target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dis. Markers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2019</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>6156493</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0310">
                     <ce:label>62</ce:label>
                     <sb:reference id="sbref0310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bellan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of Gas6 and TAM receptors in the identification of cardiopulmonary involvement in systemic sclerosis and scleroderma spectrum disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dis. Markers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2020</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>2696173</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0315">
                     <ce:label>63</ce:label>
                     <sb:reference id="sbref0315">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Binder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Kilpatrick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptor signalling and demyelination</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neurosignals</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>277</sb:first-page>
                              <sb:last-page>287</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0320">
                     <ce:label>64</ce:label>
                     <sb:reference id="sbref0320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Dendrou</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Immunopathology of multiple sclerosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>545</sb:first-page>
                              <sb:last-page>558</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0325">
                     <ce:label>65</ce:label>
                     <sb:reference id="sbref0325">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fourgeaud</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptors regulate multiple features of microglial physiology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>532</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7598</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>240</sb:first-page>
                              <sb:last-page>244</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0330">
                     <ce:label>66</ce:label>
                     <sb:reference id="sbref0330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Scutera</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>183</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3004</sb:first-page>
                              <sb:last-page>3013</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0335">
                     <ce:label>67</ce:label>
                     <sb:reference id="sbref0335">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Shankar</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>21</sb:issue-nr>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5638</sb:first-page>
                              <sb:last-page>5648</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0340">
                     <ce:label>68</ce:label>
                     <sb:reference id="sbref0340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Gruber</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted GAS6 delivery to the CNS protects axons from damage during experimental autoimmune encephalomyelitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>49</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>16320</sb:first-page>
                              <sb:last-page>16335</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0345">
                     <ce:label>69</ce:label>
                     <sb:reference id="sbref0345">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Weinger</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neuroinflammation</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>49</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0350">
                     <ce:label>70</ce:label>
                     <sb:reference id="sbref0350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Hoehn</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl-/- mice have delayed recovery and prolonged axonal damage following cuprizone toxicity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Brain Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1240</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>11</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0355">
                     <ce:label>71</ce:label>
                     <sb:reference id="sbref0355">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Binder</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5195</sb:first-page>
                              <sb:last-page>5206</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0360">
                     <ce:label>72</ce:label>
                     <sb:reference id="sbref0360">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wooliscroft</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Approaches to remyelination therapies in multiple sclerosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Treat. Options Neurol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>34</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0365">
                     <ce:label>73</ce:label>
                     <sb:reference id="sbref0365">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Sainaghi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth arrest specific gene 6 protein concentration in cerebrospinal fluid correlates with relapse severity in multiple sclerosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mediat. Inflamm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2013</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:article-number>406483</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0370">
                     <ce:label>74</ce:label>
                     <sb:reference id="sbref0370">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Sainaghi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Elevation of Gas6 protein concentration in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy (CIDP)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neurol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>269</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1-2</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>138</sb:first-page>
                              <sb:last-page>142</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0375">
                     <ce:label>75</ce:label>
                     <sb:reference id="sbref0375">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Sainaghi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth arrest specific 6 concentration is increased in the cerebrospinal fluid of patients with Alzheimer’s disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Alzheimers Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>65</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0380">
                     <ce:label>76</ce:label>
                     <sb:reference id="sbref0380">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meertens</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Host Microbe.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>544</sb:first-page>
                              <sb:last-page>557</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0385">
                     <ce:label>77</ce:label>
                     <sb:reference id="sbref0385">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Amara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mercer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Viral apoptotic mimicry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Microbiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>461</sb:first-page>
                              <sb:last-page>469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0390">
                     <ce:label>78</ce:label>
                     <sb:reference id="sbref0390">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bhattacharyya</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ebola virus uses clathrin-mediated endocytosis as an entry pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Virology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>401</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18</sb:first-page>
                              <sb:last-page>28</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0395">
                     <ce:label>79</ce:label>
                     <sb:reference id="sbref0395">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Hastings</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Loss of the TAM receptor Axl ameliorates severe Zika virus pathogenesis and reduces apoptosis in microglia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Iscience</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>339</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0400">
                     <ce:label>80</ce:label>
                     <sb:reference id="sbref0400">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Hastings</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptors are not required for Zika virus infection in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>558</sb:first-page>
                              <sb:last-page>568</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0405">
                     <ce:label>81</ce:label>
                     <sb:reference id="sbref0405">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Richard</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL-dependent infection of human fetal endothelial cells distinguishes Zika virus from other pathogenic flaviviruses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>114</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2024</sb:first-page>
                              <sb:last-page>2029</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0410">
                     <ce:label>82</ce:label>
                     <sb:reference id="sbref0410">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Microbiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>302</sb:first-page>
                              <sb:last-page>309</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0415">
                     <ce:label>83</ce:label>
                     <sb:reference id="sbref0415">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL-mediated productive infection of human endothelial cells by Zika virus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Circ. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>119</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1183</sb:first-page>
                              <sb:last-page>1189</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0420">
                     <ce:label>84</ce:label>
                     <sb:reference id="sbref0420">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Strange</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl promotes Zika virus entry and modulates the antiviral state of human Sertoli cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>mBio</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0425">
                     <ce:label>85</ce:label>
                     <sb:reference id="sbref0425">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>D’Ortenzio</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evidence of sexual transmission of Zika virus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>374</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>22</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2195</sb:first-page>
                              <sb:last-page>2198</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0430">
                     <ce:label>86</ce:label>
                     <sb:reference id="sbref0430">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Zika virus: an emergent neuropathological agent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Neurol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>479</sb:first-page>
                              <sb:last-page>489</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0435">
                     <ce:label>87</ce:label>
                     <sb:reference id="sbref0435">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Versteeg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Garcia-Sastre</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Viral tricks to grid-lock the type I interferon system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Microbiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>508</sb:first-page>
                              <sb:last-page>516</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0440">
                     <ce:label>88</ce:label>
                     <sb:reference id="sbref0440">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Fontes</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Magnetic resonance imaging findings in Guillain-Barre syndrome caused by Zika virus infection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuroradiology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>837</sb:first-page>
                              <sb:last-page>838</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0445">
                     <ce:label>89</ce:label>
                     <sb:reference id="sbref0445">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Espindola</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting of TAM receptors ameliorates fibrotic mechanisms in idiopathic pulmonary fibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Respir. Crit. Care Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>197</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1443</sb:first-page>
                              <sb:last-page>1456</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0450">
                     <ce:label>90</ce:label>
                     <sb:reference id="sbref0450">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Barcena</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hepatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>670</sb:first-page>
                              <sb:last-page>678</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0455">
                     <ce:label>91</ce:label>
                     <sb:reference id="sbref0455">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Smirne</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6/TAM signaling components as novel biomarkers of liver fibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dis. Markers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2019</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0460">
                     <ce:label>92</ce:label>
                     <sb:reference id="sbref0460">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Landolt</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Physiol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e14091</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0465">
                     <ce:label>93</ce:label>
                     <sb:reference id="sbref0465">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Holland</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1544</sb:first-page>
                              <sb:last-page>1554</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0470">
                     <ce:label>94</ce:label>
                     <sb:reference id="sbref0470">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Myers</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of potent inhibitors of receptor tyrosine kinases by ligand-based drug design and target-biased phenotypic screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2104</sb:first-page>
                              <sb:last-page>2110</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0475">
                     <ce:label>95</ce:label>
                     <sb:reference id="sbref0475">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>14</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6807</sb:first-page>
                              <sb:last-page>6825</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0480">
                     <ce:label>96</ce:label>
                     <sb:reference id="sbref0480">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.D.</ce:given-name>
                                 <ce:surname>Fleuren</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of AXL and the <ce:italic>in vitro</ce:italic> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>24</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12753</sb:first-page>
                              <sb:last-page>12768</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0485">
                     <ce:label>97</ce:label>
                     <sb:reference id="sbref0485">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ben-Batalla</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2289</sb:first-page>
                              <sb:last-page>2300</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0490">
                     <ce:label>98</ce:label>
                     <sb:reference id="sbref0490">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ben-Batalla</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>14</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2443</sb:first-page>
                              <sb:last-page>2452</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0495">
                     <ce:label>99</ce:label>
                     <sb:reference id="sbref0495">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cabozantinib (XL184) and R428 (BGB324) inhibit the growth of esophageal squamous cell carcinoma (ESCC)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1138</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0500">
                     <ce:label>100</ce:label>
                     <sb:reference id="sbref0500">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Brand</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL is a logical molecular target in head and neck squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2601</sb:first-page>
                              <sb:last-page>2612</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0505">
                     <ce:label>101</ce:label>
                     <sb:reference id="sbref0505">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tutusaus</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A functional role of GAS6/TAM in nonalcoholic steatohepatitis progression implicates AXL as therapeutic target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Mol. Gastroenterol. Hepatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>349</sb:first-page>
                              <sb:last-page>368</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0510">
                     <ce:label>102</ce:label>
                     <sb:reference id="sbref0510">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Autoimmun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>37</sb:first-page>
                              <sb:last-page>44</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0515">
                     <ce:label>103</ce:label>
                     <sb:reference id="sbref0515">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Hirschi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth arrest-specific protein-6/AXL signaling induces preeclampsia in rats</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biol. Reprod.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>199</sb:first-page>
                              <sb:last-page>210</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0520">
                     <ce:label>104</ce:label>
                     <sb:reference id="sbref0520">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Cruz-Lopez</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and characterization of a click-assembled 18-atom macrocycle that displays selective AXL kinase inhibitory activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Omega</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>25</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21620</sb:first-page>
                              <sb:last-page>21626</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0525">
                     <ce:label>105</ce:label>
                     <sb:reference id="sbref0525">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.B.</ce:given-name>
                                 <ce:surname>Ou</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL regulates mesothelioma proliferation and invasiveness</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>14</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1643</sb:first-page>
                              <sb:last-page>1652</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0530">
                     <ce:label>106</ce:label>
                     <sb:reference id="sbref0530">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jimbo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>50</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5152</sb:first-page>
                              <sb:last-page>5167</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0535">
                     <ce:label>107</ce:label>
                     <sb:reference id="sbref0535">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Fujino</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lab. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1047</sb:first-page>
                              <sb:last-page>1062</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0540">
                     <ce:label>108</ce:label>
                     <sb:reference id="sbref0540">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL is a potential target for therapeutic intervention in breast cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>68</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1905</sb:first-page>
                              <sb:last-page>1915</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0545">
                     <ce:label>109</ce:label>
                     <sb:reference id="sbref0545">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>De Boer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Onco. Targets Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>7</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0550">
                     <ce:label>110</ce:label>
                     <sb:reference id="sbref0550">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>18</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6342</sb:first-page>
                              <sb:last-page>6363</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0555">
                     <ce:label>111</ce:label>
                     <sb:reference id="sbref0555">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mori</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest. New Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>556</sb:first-page>
                              <sb:last-page>565</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0560">
                     <ce:label>112</ce:label>
                     <sb:reference id="sbref0560">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 5-5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1116</sb:first-page>
                              <sb:last-page>1119</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0565">
                     <ce:label>113</ce:label>
                     <sb:reference id="sbref0565">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1251</sb:first-page>
                              <sb:last-page>1254</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0570">
                     <ce:label>114</ce:label>
                     <sb:reference id="sbref0570">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Onken</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9876</sb:first-page>
                              <sb:last-page>9889</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0575">
                     <ce:label>115</ce:label>
                     <sb:reference id="sbref0575">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lauter</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Commun. Signal</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0580">
                     <ce:label>116</ce:label>
                     <sb:reference id="sbref0580">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yanagita</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6 induces mesangial cell proliferation via latent transcription factor STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>45</sb:issue-nr>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>42364</sb:first-page>
                              <sb:last-page>42369</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0585">
                     <ce:label>117</ce:label>
                     <sb:reference id="sbref0585">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakano</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>323</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Pt 2</sb:issue-nr>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>387</sb:first-page>
                              <sb:last-page>392</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0590">
                     <ce:label>118</ce:label>
                     <sb:reference id="sbref0590">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hasanbasic</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of gamma-carboxylation in the anti-apoptotic function of gas6</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Thromb. Haemost.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2790</sb:first-page>
                              <sb:last-page>2797</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0595">
                     <ce:label>119</ce:label>
                     <sb:reference id="sbref0595">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Paolino</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>507</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7493</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>508</sb:first-page>
                              <sb:last-page>512</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0600">
                     <ce:label>120</ce:label>
                     <sb:reference id="sbref0600">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nagai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>278</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18229</sb:first-page>
                              <sb:last-page>18234</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0605">
                     <ce:label>121</ce:label>
                     <sb:reference id="sbref0605">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Kimani</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>43908</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0610">
                     <ce:label>122</ce:label>
                     <sb:reference id="sbref0610">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cerchia</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting Axl with an high-affinity inhibitory aptamer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2291</sb:first-page>
                              <sb:last-page>2303</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0615">
                     <ce:label>123</ce:label>
                     <sb:reference id="sbref0615">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nuzzo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl-targeted delivery of the oncosuppressor miR-137 in non-small-cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Ther. Nucleic Acids</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>256</sb:first-page>
                              <sb:last-page>263</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0620">
                     <ce:label>124</ce:label>
                     <sb:reference id="sbref0620">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kanlikilicer</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic targeting of AXL receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Ther. Nucleic Acids</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>251</sb:first-page>
                              <sb:last-page>262</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0625">
                     <ce:label>125</ce:label>
                     <sb:reference id="sbref0625">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Craik</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The future of peptide-based drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>81</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>136</sb:first-page>
                              <sb:last-page>147</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0630">
                     <ce:label>126</ce:label>
                     <sb:reference id="sbref0630">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>De Rosa</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Total chemical synthesis by native chemical ligation of the all-D immunoglobulin-like domain 2 of Axl</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>894</sb:first-page>
                              <sb:last-page>905</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0635">
                     <ce:label>127</ce:label>
                     <sb:reference id="sbref0635">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.N.</ce:given-name>
                                 <ce:surname>Schumacher</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of D-peptide ligands through mirror-image phage display</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>271</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5257</sb:issue-nr>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1854</sb:first-page>
                              <sb:last-page>1857</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0640">
                     <ce:label>128</ce:label>
                     <sb:reference id="sbref0640">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>38</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5254</sb:first-page>
                              <sb:last-page>5264</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0645">
                     <ce:label>129</ce:label>
                     <sb:reference id="sbref0645">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel human anti-AXL monoclonal antibody attenuates tumour cell migration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Scand J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>90</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e12777</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0650">
                     <ce:label>130</ce:label>
                     <sb:reference id="sbref0650">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>39</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3442</sb:first-page>
                              <sb:last-page>3455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0655">
                     <ce:label>131</ce:label>
                     <sb:reference id="sbref0655">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>297</sb:first-page>
                              <sb:last-page>305</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0660">
                     <ce:label>132</ce:label>
                     <sb:reference id="sbref0660">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Leconet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>47</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5405</sb:first-page>
                              <sb:last-page>5414</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0665">
                     <ce:label>133</ce:label>
                     <sb:reference id="sbref0665">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Leconet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic activity of anti-AXL antibody against triple-negative breast cancer patient-derived xenografts and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2806</sb:first-page>
                              <sb:last-page>2816</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0670">
                     <ce:label>134</ce:label>
                     <sb:reference id="sbref0670">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Boshuizen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>203</sb:first-page>
                              <sb:last-page>212</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0675">
                     <ce:label>135</ce:label>
                     <sb:reference id="sbref0675">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Koopman</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JCI Insight</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>21</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>e128199</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0680">
                     <ce:label>136</ce:label>
                     <sb:reference id="sbref0680">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Sharp</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>Abstr. 827</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0685">
                     <ce:label>137</ce:label>
                     <sb:reference id="sbref0685">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MicroPET/CT Imaging of AXL downregulation by HSP90 inhibition in triple-negative breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Contrast Media Mol. Imaging</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2017</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1686525</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0690">
                     <ce:label>138</ce:label>
                     <sb:reference id="sbref0690">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>125</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0695">
                     <ce:label>139</ce:label>
                     <sb:reference id="sbref0695">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nimmagadda</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Imaging Axl expression in pancreatic and prostate cancer xenografts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Biophys. Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>443</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>635</sb:first-page>
                              <sb:last-page>640</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0700">
                     <ce:label>140</ce:label>
                     <sb:reference id="sbref0700">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl-targeted cancer imaging with humanized antibody h173</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Imaging Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>511</sb:first-page>
                              <sb:last-page>518</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0705">
                     <ce:label>141</ce:label>
                     <sb:reference id="sbref0705">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3974</sb:first-page>
                              <sb:last-page>3979</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0710">
                     <ce:label>142</ce:label>
                     <sb:reference id="sbref0710">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Moody</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors <ce:italic>in vivo</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>139</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1340</sb:first-page>
                              <sb:last-page>1349</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0715">
                     <ce:label>143</ce:label>
                     <sb:reference id="sbref0715">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel site contributing to growth-arrest-specific gene 6 binding to its receptors as revealed by a human monoclonal antibody</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>387</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Pt 3</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>727</sb:first-page>
                              <sb:last-page>735</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0720">
                     <ce:label>144</ce:label>
                     <sb:reference id="sbref0720">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Kariolis</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An engineered Axl ‘decoy receptor’ effectively silences the Gas6-Axl signaling axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>977</sb:first-page>
                              <sb:last-page>983</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0725">
                     <ce:label>145</ce:label>
                     <sb:reference id="sbref0725">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Kariolis</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>127</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>183</sb:first-page>
                              <sb:last-page>198</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0730">
                     <ce:label>146</ce:label>
                     <sb:reference id="sbref0730">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Engineered AXL(-ECD)-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5784</sb:first-page>
                              <sb:last-page>5792</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0735">
                     <ce:label>147</ce:label>
                     <sb:reference id="sbref0735">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Tsiperson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>GAS6 enhances repair following cuprizone-induced demyelination</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e15748</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0740">
                     <ce:label>148</ce:label>
                     <sb:reference id="sbref0740">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth arrest-specific protein 6 (Gas6) attenuates inflammatory injury and apoptosis in iodine-induced NOD.H-2(h4) mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. Immunopharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>333</sb:first-page>
                              <sb:last-page>342</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0745">
                     <ce:label>149</ce:label>
                     <sb:reference id="sbref0745">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>van den Brand</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arthritis Rheum.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>671</sb:first-page>
                              <sb:last-page>680</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0750">
                     <ce:label>150</ce:label>
                     <sb:reference id="sbref0750">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recombinant Gas6 augments Axl and facilitates immune restoration in an intracerebral hemorrhage mouse model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cereb. Blood Flow. Metab.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1971</sb:first-page>
                              <sb:last-page>1981</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0755">
                     <ce:label>151</ce:label>
                     <sb:reference id="sbref0755">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protective effects of growth arrest-specific protein 6 (Gas6) on sepsis-induced acute kidney Injury</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Inflammation</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>575</sb:first-page>
                              <sb:last-page>582</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0760">
                     <ce:label>152</ce:label>
                     <sb:reference id="sbref0760">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gas6/Axl signaling attenuates alveolar inflammation in ischemia-reperfusion-induced acute lung injury by up-regulating SOCS3-mediated pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e0219788</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0765">
                     <ce:label>153</ce:label>
                     <sb:reference id="sbref0765">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Engineering Axl specific CAR and SynNotch receptor for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3846</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0770">
                     <ce:label>154</ce:label>
                     <sb:reference id="sbref0770">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>331</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>49</sb:first-page>
                              <sb:last-page>58</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0775">
                     <ce:label>155</ce:label>
                     <sb:reference id="sbref0775">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomed. Res. Int.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2020</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4795171</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0780">
                     <ce:label>156</ce:label>
                     <sb:reference id="sbref0780">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mollard</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of a series of novel Axl kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>907</sb:first-page>
                              <sb:last-page>912</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0785">
                     <ce:label>157</ce:label>
                     <sb:reference id="sbref0785">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT–26 syngeneic mouse model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>Abstr. B148</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0790">
                     <ce:label>158</ce:label>
                     <sb:reference id="sbref0790">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Quinolone antibiotic derivatives as new selective Axl kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>166</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>318</sb:first-page>
                              <sb:last-page>327</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0795">
                     <ce:label>159</ce:label>
                     <sb:reference id="sbref0795">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Oslob</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a potent and selective aurora kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>17</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4880</sb:first-page>
                              <sb:last-page>4884</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0800">
                     <ce:label>160</ce:label>
                     <sb:reference id="sbref0800">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Burbridge</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1749</sb:first-page>
                              <sb:last-page>1762</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0805">
                     <ce:label>161</ce:label>
                     <sb:reference id="sbref0805">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1068–1069</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>33</sb:first-page>
                              <sb:last-page>40</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0810">
                     <ce:label>162</ce:label>
                     <sb:reference id="sbref0810">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Favata</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of INCB081776, a potent and selective dual AXL/MER kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>Abstr. 3759</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0815">
                     <ce:label>163</ce:label>
                     <sb:reference id="sbref0815">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mahadevan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>27</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3909</sb:first-page>
                              <sb:last-page>3919</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0820">
                     <ce:label>164</ce:label>
                     <sb:reference id="sbref0820">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>16</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7031</sb:first-page>
                              <sb:last-page>7041</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0825">
                     <ce:label>165</ce:label>
                     <sb:reference id="sbref0825">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>129</sb:first-page>
                              <sb:last-page>134</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0830">
                     <ce:label>166</ce:label>
                     <sb:reference id="sbref0830">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>UNC1062, a new and potent Mer inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>83</sb:first-page>
                              <sb:last-page>93</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0835">
                     <ce:label>167</ce:label>
                     <sb:reference id="sbref0835">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Lee-Sherick</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6722</sb:first-page>
                              <sb:last-page>6736</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0840">
                     <ce:label>168</ce:label>
                     <sb:reference id="sbref0840">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest. New Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>833</sb:first-page>
                              <sb:last-page>844</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0845">
                     <ce:label>169</ce:label>
                     <sb:reference id="sbref0845">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bonfils</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>Abstr. 1790</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0850">
                     <ce:label>170</ce:label>
                     <sb:reference id="sbref0850">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Patwardhan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4093</sb:first-page>
                              <sb:last-page>4109</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0855">
                     <ce:label>171</ce:label>
                     <sb:reference id="sbref0855">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Rho</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>74</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>253</sb:first-page>
                              <sb:last-page>262</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0860">
                     <ce:label>172</ce:label>
                     <sb:reference id="sbref0860">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>556</sb:first-page>
                              <sb:last-page>568</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0865">
                     <ce:label>173</ce:label>
                     <sb:reference id="sbref0865">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Qian</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8009</sb:first-page>
                              <sb:last-page>8016</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0870">
                     <ce:label>174</ce:label>
                     <sb:reference id="sbref0870">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Ruvolo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Haematologica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2048</sb:first-page>
                              <sb:last-page>2057</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0875">
                     <ce:label>175</ce:label>
                     <sb:reference id="sbref0875">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yasuhiro</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of an Axl/Mer dual inhibitor, ONO-9330547: promising single agent activity in an acute myeloid leukemia (AML) model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>124</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>21</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>999</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0880">
                     <ce:label>176</ce:label>
                     <sb:reference id="sbref0880">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yokoyama</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Immuno-oncological efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small-molecule kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1996</sb:first-page>
                              <sb:last-page>2008</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0885">
                     <ce:label>177</ce:label>
                     <sb:reference id="sbref0885">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Gajiwala</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>292</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>38</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15705</sb:first-page>
                              <sb:last-page>15716</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0890">
                     <ce:label>178</ce:label>
                     <sb:reference id="sbref0890">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sasaki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>46</sb:issue-nr>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>44164</sb:first-page>
                              <sb:last-page>44170</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
            <ce:biography id="vt0005" view="all">
               <ce:link xlink:href="pii:S1359644620303792/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx3"/></ce:link>
               <ce:simple-para id="spar0080" view="all">
                  <ce:bold>Rossella Di Stasi</ce:bold> was awarded a PhD in molecular biotechnology in 2009 from the University of Naples ‘Federico II’. Her research mainly concerns the expression and characterization of recombinant proteins and the use of phage display libraries for the screening of peptide–protein interactions. Currently, she is a research scientist at CNR, Naples, where, under the supervision of Luca D’Andrea, she spent her postdoctoral training focusing mainly on the study of VEGF and its receptors for the development of new bioactive molecules able to modulate angiogenesis. Over the past 4 years, she dedicated part of her research to the Axl/Gas6 molecular system and its involvement in multiple sclerosis and cancer.</ce:simple-para>
            </ce:biography>
            <ce:biography id="vt0010" view="all">
               <ce:link xlink:href="pii:S1359644620303792/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx2"/></ce:link>
               <ce:simple-para id="spar0085" view="all">
                  <ce:bold>Lucia De Rosa</ce:bold> was awarded a PhD in biotechnology from the University of Naples ‘Federico II’ and is currently a research scientist at CNR, Naples. Her recent research activity was supported by the Fondazione ‘Umberto Veronesi’ (Milan, Italy) and is aimed at developing novel peptide-based molecules targeting the Axl receptor with therapeutic or diagnostic applications. Her main interests are in drug discovery, protein synthesis, and site-specific modification using chemical ligation methodologies.</ce:simple-para>
            </ce:biography>
            <ce:biography id="vt0015" view="all">
               <ce:link xlink:href="pii:S1359644620303792/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx1"/></ce:link>
               <ce:simple-para id="spar0090" view="all">
                  <ce:bold>Luca D. D’Andrea</ce:bold> is a senior research scientist at CNR, Italy. He was awarded a PhD in chemistry from the University of Naples ‘Federico II’, then he moved to Yale University as Postdoctoral Associate at the Department of Molecular Biophysics and Biochemistry working with L. Regan on the design of TPR proteins. Since 2001, he has been a staff scientist at CNR, where he has established his own group working on the development of novel peptides and proteins for therapeutic and diagnostic applications, mainly focusing on VEGFR and Axl binders. His research activity also focuses on the chemical synthesis and bioconjugation of proteins.</ce:simple-para>
            </ce:biography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>